Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sarcoidosis and calcium homeostasis disturbances—Do we know where we stand?</title><author><name sortKey="Gwadera, Lukasz" sort="Gwadera, Lukasz" uniqKey="Gwadera L" first="Łukasz" last="Gwadera">Łukasz Gwadera</name><affiliation><nlm:aff id="aff1-1479973119878713">Department of Pneumology and Allergy, Chair of Internal Medicine, Medical University of Lodz, Poland</nlm:aff></affiliation></author><author><name sortKey="Bialas, Adam Jerzy" sort="Bialas, Adam Jerzy" uniqKey="Bialas A" first="Adam Jerzy" last="Białas">Adam Jerzy Białas</name><affiliation><nlm:aff id="aff1-1479973119878713">Department of Pneumology and Allergy, Chair of Internal Medicine, Medical University of Lodz, Poland</nlm:aff></affiliation></author><author><name sortKey="Iwa Ski, Mikolaj Aleksander" sort="Iwa Ski, Mikolaj Aleksander" uniqKey="Iwa Ski M" first="Mikołaj Aleksander" last="Iwa Ski">Mikołaj Aleksander Iwa Ski</name><affiliation><nlm:aff id="aff1-1479973119878713">Department of Pneumology and Allergy, Chair of Internal Medicine, Medical University of Lodz, Poland</nlm:aff></affiliation></author><author><name sortKey="G Rski, Pawel" sort="G Rski, Pawel" uniqKey="G Rski P" first="Paweł" last="G Rski">Paweł G Rski</name><affiliation><nlm:aff id="aff1-1479973119878713">Department of Pneumology and Allergy, Chair of Internal Medicine, Medical University of Lodz, Poland</nlm:aff></affiliation></author><author><name sortKey="Piotrowski, Wojciech Jerzy" sort="Piotrowski, Wojciech Jerzy" uniqKey="Piotrowski W" first="Wojciech Jerzy" last="Piotrowski">Wojciech Jerzy Piotrowski</name><affiliation><nlm:aff id="aff1-1479973119878713">Department of Pneumology and Allergy, Chair of Internal Medicine, Medical University of Lodz, Poland</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31718265</idno><idno type="pmc">6854763</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854763</idno><idno type="RBID">PMC:6854763</idno><idno type="doi">10.1177/1479973119878713</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000937</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000937</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Sarcoidosis and calcium homeostasis disturbances—Do we know where we stand?</title><author><name sortKey="Gwadera, Lukasz" sort="Gwadera, Lukasz" uniqKey="Gwadera L" first="Łukasz" last="Gwadera">Łukasz Gwadera</name><affiliation><nlm:aff id="aff1-1479973119878713">Department of Pneumology and Allergy, Chair of Internal Medicine, Medical University of Lodz, Poland</nlm:aff></affiliation></author><author><name sortKey="Bialas, Adam Jerzy" sort="Bialas, Adam Jerzy" uniqKey="Bialas A" first="Adam Jerzy" last="Białas">Adam Jerzy Białas</name><affiliation><nlm:aff id="aff1-1479973119878713">Department of Pneumology and Allergy, Chair of Internal Medicine, Medical University of Lodz, Poland</nlm:aff></affiliation></author><author><name sortKey="Iwa Ski, Mikolaj Aleksander" sort="Iwa Ski, Mikolaj Aleksander" uniqKey="Iwa Ski M" first="Mikołaj Aleksander" last="Iwa Ski">Mikołaj Aleksander Iwa Ski</name><affiliation><nlm:aff id="aff1-1479973119878713">Department of Pneumology and Allergy, Chair of Internal Medicine, Medical University of Lodz, Poland</nlm:aff></affiliation></author><author><name sortKey="G Rski, Pawel" sort="G Rski, Pawel" uniqKey="G Rski P" first="Paweł" last="G Rski">Paweł G Rski</name><affiliation><nlm:aff id="aff1-1479973119878713">Department of Pneumology and Allergy, Chair of Internal Medicine, Medical University of Lodz, Poland</nlm:aff></affiliation></author><author><name sortKey="Piotrowski, Wojciech Jerzy" sort="Piotrowski, Wojciech Jerzy" uniqKey="Piotrowski W" first="Wojciech Jerzy" last="Piotrowski">Wojciech Jerzy Piotrowski</name><affiliation><nlm:aff id="aff1-1479973119878713">Department of Pneumology and Allergy, Chair of Internal Medicine, Medical University of Lodz, Poland</nlm:aff></affiliation></author></analytic><series><title level="j">Chronic Respiratory Disease</title><idno type="ISSN">1479-9723</idno><idno type="eISSN">1479-9731</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The majority of cases involving hypercalcemia in the setting of sarcoidosis are explained by the overproduction of calcitriol by activated macrophages. Vitamin D takes part in the regulation of granuloma formation. However, using vitamin D metabolites to assess the activity of the disease is still problematic, and its usefulness is disputable. In some cases, though, a calcium metabolism disorder could be a valuable tool (i.e. as a marker of extrathoracic sarcoidosis). Although sarcoidosis does not cause a decrease in bone mineral density, increased incidence of vertebral deformities is noted. Despite increasing knowledge about calcium homeostasis disorders in patients with sarcoidosis, there is still a need for clear guidelines regarding calcium and vitamin D supplementation in these patients.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Blau, Je" uniqKey="Blau J">JE Blau</name></author><author><name sortKey="Collins, Mt" uniqKey="Collins M">MT Collins</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yokota, H" uniqKey="Yokota H">H Yokota</name></author><author><name sortKey="Raposo, Jf" uniqKey="Raposo J">JF Raposo</name></author><author><name sortKey="Chen, A" uniqKey="Chen A">A Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kamphuis, Ls" uniqKey="Kamphuis L">LS Kamphuis</name></author><author><name sortKey="Bonte Mineur, F" uniqKey="Bonte Mineur F">F Bonte-Mineur</name></author><author><name sortKey="Van Laar, Ja" uniqKey="Van Laar J">JA van Laar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Adams, Js" uniqKey="Adams J">JS Adams</name></author><author><name sortKey="Hewison, M" uniqKey="Hewison M">M Hewison</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rottoli, P" uniqKey="Rottoli P">P Rottoli</name></author><author><name sortKey="Muscettola, M" uniqKey="Muscettola M">M Muscettola</name></author><author><name sortKey="Grasso, G" uniqKey="Grasso G">G Grasso</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muscettola, M" uniqKey="Muscettola M">M Muscettola</name></author><author><name sortKey="Grasso, G" uniqKey="Grasso G">G Grasso</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, K" uniqKey="Muller K">K Müller</name></author><author><name sortKey="Bendtzen, K" uniqKey="Bendtzen K">K. Bendtzen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y Zhang</name></author><author><name sortKey="Leung, Dym" uniqKey="Leung D">DYM Leung</name></author><author><name sortKey="Richers, Bn" uniqKey="Richers B">BN Richers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ohta, M" uniqKey="Ohta M">M Ohta</name></author><author><name sortKey="Okabe, T" uniqKey="Okabe T">T Okabe</name></author><author><name sortKey="Ozawa, K" uniqKey="Ozawa K">K Ozawa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Penna, G" uniqKey="Penna G">G Penna</name></author><author><name sortKey="Adorini, L" uniqKey="Adorini L">L. Adorini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bucova, M" uniqKey="Bucova M">M Bucova</name></author><author><name sortKey="Suchankova, M" uniqKey="Suchankova M">M Suchankova</name></author><author><name sortKey="Tibenska, E" uniqKey="Tibenska E">E Tibenska</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barna, Bp" uniqKey="Barna B">BP Barna</name></author><author><name sortKey="Culver, Da" uniqKey="Culver D">DA Culver</name></author><author><name sortKey="Kanchwala, A" uniqKey="Kanchwala A">A Kanchwala</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Biyoudi Vouenze, R" uniqKey="Biyoudi Vouenze R">R Biyoudi-Vouenze</name></author><author><name sortKey="Cadranel, J" uniqKey="Cadranel J">J Cadranel</name></author><author><name sortKey="Valeyre, D" uniqKey="Valeyre D">D Valeyre</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Niimi, T" uniqKey="Niimi T">T Niimi</name></author><author><name sortKey="Tomita, H" uniqKey="Tomita H">H Tomita</name></author><author><name sortKey="Sato, S" uniqKey="Sato S">S Sato</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Petkovic, Tr" uniqKey="Petkovic T">TR Petkovic</name></author><author><name sortKey="Pejcic, T" uniqKey="Pejcic T">T Pejcic</name></author><author><name sortKey="Marinkovic, M" uniqKey="Marinkovic M">M Marinkovic</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Taibi, L" uniqKey="Taibi L">L Taibi</name></author><author><name sortKey="Boursier, C" uniqKey="Boursier C">C Boursier</name></author><author><name sortKey="Clodic, G" uniqKey="Clodic G">G Clodic</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martinez Bravo, M J" uniqKey="Martinez Bravo M">M-J Martinez-Bravo</name></author><author><name sortKey="Wahlund, Cje" uniqKey="Wahlund C">CJE Wahlund</name></author><author><name sortKey="Qazi, Kr" uniqKey="Qazi K">KR Qazi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Milman, N" uniqKey="Milman N">N Milman</name></author><author><name sortKey="Thymann, M" uniqKey="Thymann M">M Thymann</name></author><author><name sortKey="Graudal, N" uniqKey="Graudal N">N Graudal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Renaghan, Ad" uniqKey="Renaghan A">AD Renaghan</name></author><author><name sortKey="Rosner, Mh" uniqKey="Rosner M">MH Rosner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Donovan, Pj" uniqKey="Donovan P">PJ Donovan</name></author><author><name sortKey="Sundac, L" uniqKey="Sundac L">L Sundac</name></author><author><name sortKey="Pretorius, Cj" uniqKey="Pretorius C">CJ Pretorius</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Soyfoo, Ms" uniqKey="Soyfoo M">MS Soyfoo</name></author><author><name sortKey="Brenner, K" uniqKey="Brenner K">K Brenner</name></author><author><name sortKey="Paesmans, M" uniqKey="Paesmans M">M Paesmans</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Morimoto, T" uniqKey="Morimoto T">T Morimoto</name></author><author><name sortKey="Azuma, A" uniqKey="Azuma A">A Azuma</name></author><author><name sortKey="Abe, S" uniqKey="Abe S">S Abe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ungprasert, P" uniqKey="Ungprasert P">P Ungprasert</name></author><author><name sortKey="Crowson, Cs" uniqKey="Crowson C">CS Crowson</name></author><author><name sortKey="Matteson, El" uniqKey="Matteson E">EL Matteson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="James, Dg" uniqKey="James D">DG James</name></author><author><name sortKey="Neville, E" uniqKey="Neville E">E Neville</name></author><author><name sortKey="Siltzbach, Le" uniqKey="Siltzbach L">LE Siltzbach</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Studdy, Pr" uniqKey="Studdy P">PR Studdy</name></author><author><name sortKey="Bird, R" uniqKey="Bird R">R Bird</name></author><author><name sortKey="Neville, E" uniqKey="Neville E">E Neville</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Baughman, Rp" uniqKey="Baughman R">RP Baughman</name></author><author><name sortKey="Teirstein, As" uniqKey="Teirstein A">AS Teirstein</name></author><author><name sortKey="Judson, Ma" uniqKey="Judson M">MA Judson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smith, C" uniqKey="Smith C">C Smith</name></author><author><name sortKey="Feldman, C" uniqKey="Feldman C">C Feldman</name></author><author><name sortKey="Reyneke, J" uniqKey="Reyneke J">J Reyneke</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mahevas, M" uniqKey="Mahevas M">M Mahévas</name></author><author><name sortKey="Lescure, Fx" uniqKey="Lescure F">FX Lescure</name></author><author><name sortKey="Boffa, J J" uniqKey="Boffa J">J-J Boffa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Baughman, Rp" uniqKey="Baughman R">RP Baughman</name></author><author><name sortKey="Janovcik, J" uniqKey="Janovcik J">J Janovcik</name></author><author><name sortKey="Ray, M" uniqKey="Ray M">M Ray</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sawahata, M" uniqKey="Sawahata M">M Sawahata</name></author><author><name sortKey="Sugiyama, Y" uniqKey="Sugiyama Y">Y Sugiyama</name></author><author><name sortKey="Nakamura, Y" uniqKey="Nakamura Y">Y Nakamura</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brito Zer N, P" uniqKey="Brito Zer N P">P Brito-Zerón</name></author><author><name sortKey="Sellares, J" uniqKey="Sellares J">J Sellarés</name></author><author><name sortKey="Bosch, X" uniqKey="Bosch X">X Bosch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Abernathy, Rs" uniqKey="Abernathy R">RS Abernathy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoffmann, Al" uniqKey="Hoffmann A">AL Hoffmann</name></author><author><name sortKey="Milman, N" uniqKey="Milman N">N Milman</name></author><author><name sortKey="Byg, Ke" uniqKey="Byg K">KE Byg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Robinson, Pj" uniqKey="Robinson P">PJ Robinson</name></author><author><name sortKey="Olinsky, A" uniqKey="Olinsky A">A Olinsky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smith, Mj" uniqKey="Smith M">MJ Smith</name></author><author><name sortKey="Hey, Gb" uniqKey="Hey G">GB Hey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Papapoulos, Se" uniqKey="Papapoulos S">SE Papapoulos</name></author><author><name sortKey="Clemens, Tl" uniqKey="Clemens T">TL Clemens</name></author><author><name sortKey="Fraher, Lj" uniqKey="Fraher L">LJ Fraher</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cronin, Cc" uniqKey="Cronin C">CC Cronin</name></author><author><name sortKey="Dinneen, Sf" uniqKey="Dinneen S">SF Dinneen</name></author><author><name sortKey="O Ahony, Ms" uniqKey="O Ahony M">MS O’Mahony</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wiemeyer, A" uniqKey="Wiemeyer A">A Wiemeyer</name></author><author><name sortKey="Schwarze, Ew" uniqKey="Schwarze E">EW Schwarze</name></author><author><name sortKey="Mathias, K" uniqKey="Mathias K">K Mathias</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rossman, Md" uniqKey="Rossman M">MD Rossman</name></author><author><name sortKey="Thompson, B" uniqKey="Thompson B">B Thompson</name></author><author><name sortKey="Frederick, M" uniqKey="Frederick M">M Frederick</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lancina Martin, Ja" uniqKey="Lancina Martin J">JA Lancina Martín</name></author><author><name sortKey="Garcia Freire, C" uniqKey="Garcia Freire C">C García Freire</name></author><author><name sortKey="Busto Casta N, L" uniqKey="Busto Casta N L">L Busto Castañón</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Iannuzzi, Mc" uniqKey="Iannuzzi M">MC Iannuzzi</name></author><author><name sortKey="Rybicki, Ba" uniqKey="Rybicki B">BA Rybicki</name></author><author><name sortKey="Teirstein, As" uniqKey="Teirstein A">AS Teirstein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Berliner, Ar" uniqKey="Berliner A">AR Berliner</name></author><author><name sortKey="Haas, M" uniqKey="Haas M">M Haas</name></author><author><name sortKey="Choi, Mj" uniqKey="Choi M">MJ Choi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bell, Nh" uniqKey="Bell N">NH Bell</name></author><author><name sortKey="Stern, Ph" uniqKey="Stern P">PH Stern</name></author><author><name sortKey="Pantzer, E" uniqKey="Pantzer E">E Pantzer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barbour, Gl" uniqKey="Barbour G">GL Barbour</name></author><author><name sortKey="Coburn, Jw" uniqKey="Coburn J">JW Coburn</name></author><author><name sortKey="Slatopolsky, E" uniqKey="Slatopolsky E">E Slatopolsky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maesaka, Jk" uniqKey="Maesaka J">JK Maesaka</name></author><author><name sortKey="Batuman, V" uniqKey="Batuman V">V Batuman</name></author><author><name sortKey="Pablo, Nc" uniqKey="Pablo N">NC Pablo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mason, Rs" uniqKey="Mason R">RS Mason</name></author><author><name sortKey="Frankel, T" uniqKey="Frankel T">T Frankel</name></author><author><name sortKey="Chan, Yl" uniqKey="Chan Y">YL Chan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Adams, Js" uniqKey="Adams J">JS Adams</name></author><author><name sortKey="Sharma, Op" uniqKey="Sharma O">OP Sharma</name></author><author><name sortKey="Gacad, Ma" uniqKey="Gacad M">MA Gacad</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Adams, Js" uniqKey="Adams J">JS Adams</name></author><author><name sortKey="Singer, Fr" uniqKey="Singer F">FR Singer</name></author><author><name sortKey="Gacad, Ma" uniqKey="Gacad M">MA Gacad</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Adams, Js" uniqKey="Adams J">JS Adams</name></author><author><name sortKey="Chen, H" uniqKey="Chen H">H Chen</name></author><author><name sortKey="Chun, R" uniqKey="Chun R">R Chun</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reichel, H" uniqKey="Reichel H">H Reichel</name></author><author><name sortKey="Koeffler, Hp" uniqKey="Koeffler H">HP Koeffler</name></author><author><name sortKey="Barbers, R" uniqKey="Barbers R">R Barbers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Adams, Js" uniqKey="Adams J">JS Adams</name></author><author><name sortKey="Modlin, Rl" uniqKey="Modlin R">RL Modlin</name></author><author><name sortKey="Diz, Mm" uniqKey="Diz M">MM Diz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dusso, As" uniqKey="Dusso A">AS Dusso</name></author><author><name sortKey="Kamimura, S" uniqKey="Kamimura S">S Kamimura</name></author><author><name sortKey="Gallieni, M" uniqKey="Gallieni M">M Gallieni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Adams, Js" uniqKey="Adams J">JS Adams</name></author><author><name sortKey="Gacad, Ma" uniqKey="Gacad M">MA Gacad</name></author><author><name sortKey="Diz, Mm" uniqKey="Diz M">MM Diz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lawrence, Ec" uniqKey="Lawrence E">EC Lawrence</name></author><author><name sortKey="Berger, Mb" uniqKey="Berger M">MB Berger</name></author><author><name sortKey="Brousseau, Kp" uniqKey="Brousseau K">KP Brousseau</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Logan, T" uniqKey="Logan T">T Logan</name></author><author><name sortKey="Bensadoun, E" uniqKey="Bensadoun E">E Bensadoun</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yokomura, K" uniqKey="Yokomura K">K Yokomura</name></author><author><name sortKey="Suda, T" uniqKey="Suda T">T Suda</name></author><author><name sortKey="Sasaki, S" uniqKey="Sasaki S">S Sasaki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stoffels, K" uniqKey="Stoffels K">K Stoffels</name></author><author><name sortKey="Overbergh, L" uniqKey="Overbergh L">L Overbergh</name></author><author><name sortKey="Giulietti, A" uniqKey="Giulietti A">A Giulietti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Unsal, A" uniqKey="Unsal A">A Unsal</name></author><author><name sortKey="Basturk, T" uniqKey="Basturk T">T Basturk</name></author><author><name sortKey="Koc, Y" uniqKey="Koc Y">Y Koc</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Berlin, Jl" uniqKey="Berlin J">JL Berlin</name></author><author><name sortKey="Palamaner Subash Shantha, G" uniqKey="Palamaner Subash Shantha G">G Palamaner Subash Shantha</name></author><author><name sortKey="Yeager, H" uniqKey="Yeager H">H Yeager</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shrayyef, Mz" uniqKey="Shrayyef M">MZ Shrayyef</name></author><author><name sortKey="Depapp, Z" uniqKey="Depapp Z">Z DePapp</name></author><author><name sortKey="Cave, Wt" uniqKey="Cave W">WT Cave</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Falk, S" uniqKey="Falk S">S Falk</name></author><author><name sortKey="Kratzsch, J" uniqKey="Kratzsch J">J Kratzsch</name></author><author><name sortKey="Paschke, R" uniqKey="Paschke R">R Paschke</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Basile, Jn" uniqKey="Basile J">JN Basile</name></author><author><name sortKey="Liel, Y" uniqKey="Liel Y">Y Liel</name></author><author><name sortKey="Shary, J" uniqKey="Shary J">J Shary</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stern, Ph" uniqKey="Stern P">PH Stern</name></author><author><name sortKey="De Olazabal, J" uniqKey="De Olazabal J">J De Olazabal</name></author><author><name sortKey="Bell, Nh" uniqKey="Bell N">NH Bell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hamada, K" uniqKey="Hamada K">K Hamada</name></author><author><name sortKey="Nagai, S" uniqKey="Nagai S">S Nagai</name></author><author><name sortKey="Tsutsumi, T" uniqKey="Tsutsumi T">T Tsutsumi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Adams, Js" uniqKey="Adams J">JS Adams</name></author><author><name sortKey="Gacad, Ma" uniqKey="Gacad M">MA Gacad</name></author><author><name sortKey="Anders, A" uniqKey="Anders A">A Anders</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alberts, C" uniqKey="Alberts C">C Alberts</name></author><author><name sortKey="Van Den Berg, H" uniqKey="Van Den Berg H">H. van den Berg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Krikorian, A" uniqKey="Krikorian A">A Krikorian</name></author><author><name sortKey="Shah, S" uniqKey="Shah S">S Shah</name></author><author><name sortKey="Wasman, J" uniqKey="Wasman J">J Wasman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Raalte, Dh" uniqKey="Van Raalte D">DH van Raalte</name></author><author><name sortKey="Goorden, Sm" uniqKey="Goorden S">SM Goorden</name></author><author><name sortKey="Kemper, Ea" uniqKey="Kemper E">EA Kemper</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zeimer, Hj" uniqKey="Zeimer H">HJ Zeimer</name></author><author><name sortKey="Greenaway, Tm" uniqKey="Greenaway T">TM Greenaway</name></author><author><name sortKey="Slavin, J" uniqKey="Slavin J">J Slavin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fierer, J" uniqKey="Fierer J">J Fierer</name></author><author><name sortKey="Burton, Dw" uniqKey="Burton D">DW Burton</name></author><author><name sortKey="Haghighi, P" uniqKey="Haghighi P">P Haghighi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pandian, Mr" uniqKey="Pandian M">MR Pandian</name></author><author><name sortKey="Morgan, Ch" uniqKey="Morgan C">CH Morgan</name></author><author><name sortKey="Carlton, E" uniqKey="Carlton E">E Carlton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bucht, E" uniqKey="Bucht E">E Bucht</name></author><author><name sortKey="Eklund, A" uniqKey="Eklund A">A Eklund</name></author><author><name sortKey="Toss, G" uniqKey="Toss G">G Toss</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Heijckmann, Ac" uniqKey="Heijckmann A">AC Heijckmann</name></author><author><name sortKey="Huijberts, Msp" uniqKey="Huijberts M">MSP Huijberts</name></author><author><name sortKey="De Vries, J" uniqKey="De Vries J">J De Vries</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Heijckmann, Ac" uniqKey="Heijckmann A">AC Heijckmann</name></author><author><name sortKey="Drent, M" uniqKey="Drent M">M Drent</name></author><author><name sortKey="Dumitrescu, B" uniqKey="Dumitrescu B">B Dumitrescu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bolland, Mj" uniqKey="Bolland M">MJ Bolland</name></author><author><name sortKey="Wilsher, Ml" uniqKey="Wilsher M">ML Wilsher</name></author><author><name sortKey="Grey, A" uniqKey="Grey A">A Grey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bours, S" uniqKey="Bours S">S Bours</name></author><author><name sortKey="De Vries, F" uniqKey="De Vries F">F de Vries</name></author><author><name sortKey="Van Den Bergh, Jpw" uniqKey="Van Den Bergh J">JPW van den Bergh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oshagbemi, Oa" uniqKey="Oshagbemi O">OA Oshagbemi</name></author><author><name sortKey="Driessen, Jhm" uniqKey="Driessen J">JHM Driessen</name></author><author><name sortKey="Pieffers, A" uniqKey="Pieffers A">A Pieffers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saidenberg Kermanac, N" uniqKey="Saidenberg Kermanac N">N Saidenberg-Kermanac’h</name></author><author><name sortKey="Semerano, L" uniqKey="Semerano L">L Semerano</name></author><author><name sortKey="Nunes, H" uniqKey="Nunes H">H Nunes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bolland, Mj" uniqKey="Bolland M">MJ Bolland</name></author><author><name sortKey="Wilsher, Ml" uniqKey="Wilsher M">ML Wilsher</name></author><author><name sortKey="Grey, A" uniqKey="Grey A">A Grey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Amin, S" uniqKey="Amin S">S Amin</name></author><author><name sortKey="Lavalley, Mp" uniqKey="Lavalley M">MP LaValley</name></author><author><name sortKey="Simms, Rw" uniqKey="Simms R">RW Simms</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Allen, Cs" uniqKey="Allen C">CS Allen</name></author><author><name sortKey="Yeung, Jh" uniqKey="Yeung J">JH Yeung</name></author><author><name sortKey="Vandermeer, B" uniqKey="Vandermeer B">B Vandermeer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Amiche, Ma" uniqKey="Amiche M">MA Amiche</name></author><author><name sortKey="Albaum, Jm" uniqKey="Albaum J">JM Albaum</name></author><author><name sortKey="Tadrous, M" uniqKey="Tadrous M">M Tadrous</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boon, Es" uniqKey="Boon E">ES Boon</name></author><author><name sortKey="Cozijn, D" uniqKey="Cozijn D">D Cozijn</name></author><author><name sortKey="Brombacher, Pj" uniqKey="Brombacher P">PJ Brombacher</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sarathi, V" uniqKey="Sarathi V">V Sarathi</name></author><author><name sortKey="Karethimmaiah, H" uniqKey="Karethimmaiah H">H Karethimmaiah</name></author><author><name sortKey="Goel, A" uniqKey="Goel A">A Goel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sodhi, A" uniqKey="Sodhi A">A Sodhi</name></author><author><name sortKey="Aldrich, T" uniqKey="Aldrich T">T. Aldrich</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Capolongo, G" uniqKey="Capolongo G">G Capolongo</name></author><author><name sortKey="Xu, Lhr" uniqKey="Xu L">LHR Xu</name></author><author><name sortKey="Accardo, M" uniqKey="Accardo M">M Accardo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kiani, A" uniqKey="Kiani A">A Kiani</name></author><author><name sortKey="Abedini, A" uniqKey="Abedini A">A Abedini</name></author><author><name sortKey="Adcock, Im" uniqKey="Adcock I">IM Adcock</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bansal, As" uniqKey="Bansal A">AS Bansal</name></author><author><name sortKey="Bruce, J" uniqKey="Bruce J">J Bruce</name></author><author><name sortKey="Hogan, Pg" uniqKey="Hogan P">PG Hogan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kavathia, D" uniqKey="Kavathia D">D Kavathia</name></author><author><name sortKey="Buckley, Jd" uniqKey="Buckley J">JD Buckley</name></author><author><name sortKey="Rao, D" uniqKey="Rao D">D Rao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Infante, Jr" uniqKey="Infante J">JR Infante</name></author><author><name sortKey="Pacheco, C" uniqKey="Pacheco C">C Pacheco</name></author><author><name sortKey="Torres Avisbal, M" uniqKey="Torres Avisbal M">M Torres-Avisbal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sharma, Op" uniqKey="Sharma O">OP Sharma</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Burke, Rr" uniqKey="Burke R">RR Burke</name></author><author><name sortKey="Rybicki, Ba" uniqKey="Rybicki B">BA Rybicki</name></author><author><name sortKey="Rao, Ds" uniqKey="Rao D">DS Rao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Adams, Js" uniqKey="Adams J">JS Adams</name></author><author><name sortKey="Sharma, Op" uniqKey="Sharma O">OP Sharma</name></author><author><name sortKey="Diz, Mm" uniqKey="Diz M">MM Diz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bia, Mj" uniqKey="Bia M">MJ Bia</name></author><author><name sortKey="Insogna, K" uniqKey="Insogna K">K Insogna</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barre, Pe" uniqKey="Barre P">PE Barré</name></author><author><name sortKey="Gascon Barre, M" uniqKey="Gascon Barre M">M Gascon-Barré</name></author><author><name sortKey="Meakins, Jl" uniqKey="Meakins J">JL Meakins</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="O Eary, Tj" uniqKey="O Eary T">TJ O’Leary</name></author><author><name sortKey="Jones, G" uniqKey="Jones G">G Jones</name></author><author><name sortKey="Yip, A" uniqKey="Yip A">A Yip</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thumfart, J" uniqKey="Thumfart J">J Thumfart</name></author><author><name sortKey="Muller, D" uniqKey="Muller D">D Müller</name></author><author><name sortKey="Rudolph, B" uniqKey="Rudolph B">B Rudolph</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Huffstutter, Jg" uniqKey="Huffstutter J">JG Huffstutter</name></author><author><name sortKey="Huffstutter, Je" uniqKey="Huffstutter J">JE Huffstutter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dwarakanathan, A" uniqKey="Dwarakanathan A">A Dwarakanathan</name></author><author><name sortKey="Ryan, Wg" uniqKey="Ryan W">WG Ryan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Waron, M" uniqKey="Waron M">M Waron</name></author><author><name sortKey="Weissgarten, J" uniqKey="Weissgarten J">J Weissgarten</name></author><author><name sortKey="Gil, I" uniqKey="Gil I">I Gil</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Littlewood, T" uniqKey="Littlewood T">T Littlewood</name></author><author><name sortKey="Hunter, A" uniqKey="Hunter A">A Hunter</name></author><author><name sortKey="Beck, P" uniqKey="Beck P">P Beck</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Meyrier, A" uniqKey="Meyrier A">A Meyrier</name></author><author><name sortKey="Valeyre, D" uniqKey="Valeyre D">D Valeyre</name></author><author><name sortKey="Bouillon, R" uniqKey="Bouillon R">R Bouillon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fuss, M" uniqKey="Fuss M">M Fuss</name></author><author><name sortKey="Pepersack, T" uniqKey="Pepersack T">T Pepersack</name></author><author><name sortKey="Gillet, C" uniqKey="Gillet C">C Gillet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rizzato, G" uniqKey="Rizzato G">G Rizzato</name></author><author><name sortKey="Colombo, P" uniqKey="Colombo P">P Colombo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lemann, J" uniqKey="Lemann J">J Lemann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thomas, Wc" uniqKey="Thomas W">WC Thomas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rohmer, J" uniqKey="Rohmer J">J Rohmer</name></author><author><name sortKey="Hadjadj, J" uniqKey="Hadjadj J">J Hadjadj</name></author><author><name sortKey="Bouzerara, A" uniqKey="Bouzerara A">A Bouzerara</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Chron Respir Dis</journal-id><journal-id journal-id-type="iso-abbrev">Chron Respir Dis</journal-id><journal-id journal-id-type="publisher-id">CRD</journal-id><journal-id journal-id-type="hwp">spcrd</journal-id><journal-title-group><journal-title>Chronic Respiratory Disease</journal-title></journal-title-group><issn pub-type="ppub">1479-9723</issn><issn pub-type="epub">1479-9731</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31718265</article-id><article-id pub-id-type="pmc">6854763</article-id><article-id pub-id-type="doi">10.1177/1479973119878713</article-id><article-id pub-id-type="publisher-id">10.1177_1479973119878713</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Paper</subject></subj-group></article-categories><title-group><article-title>Sarcoidosis and calcium homeostasis disturbances—Do we know where we stand?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gwadera</surname><given-names>Łukasz</given-names></name><xref ref-type="aff" rid="aff1-1479973119878713">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3501-167X</contrib-id><name><surname>Białas</surname><given-names>Adam Jerzy</given-names></name><xref ref-type="aff" rid="aff1-1479973119878713">1</xref><xref ref-type="corresp" rid="corresp1-1479973119878713"></xref></contrib><contrib contrib-type="author"><name><surname>Iwański</surname><given-names>Mikołaj Aleksander</given-names></name><xref ref-type="aff" rid="aff1-1479973119878713">1</xref></contrib><contrib contrib-type="author"><name><surname>Górski</surname><given-names>Paweł</given-names></name><xref ref-type="aff" rid="aff1-1479973119878713">1</xref></contrib><contrib contrib-type="author"><name><surname>Piotrowski</surname><given-names>Wojciech Jerzy</given-names></name><xref ref-type="aff" rid="aff1-1479973119878713">1</xref></contrib></contrib-group><aff id="aff1-1479973119878713"><label>1</label>Department of Pneumology and Allergy, Chair of Internal Medicine, Medical University of Lodz, Poland</aff><author-notes><corresp id="corresp1-1479973119878713">Adam Jerzy Białas, Department of Pneumology and Allergy, Medical University of Lodz, 22 Kopcińskiego Street, 90-153 Lodz, Poland. Email: <email>adam.bialas@umed.lodz.pl</email></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2019</year></pub-date><volume>16</volume><elocation-id>1479973119878713</elocation-id><history><date date-type="received"><day>12</day><month>3</month><year>2019</year></date><date date-type="rev-recd"><day>29</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>3</day><month>9</month><year>2019</year></date></history><permissions><copyright-statement>© The Author(s) 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><p>The majority of cases involving hypercalcemia in the setting of sarcoidosis are explained by the overproduction of calcitriol by activated macrophages. Vitamin D takes part in the regulation of granuloma formation. However, using vitamin D metabolites to assess the activity of the disease is still problematic, and its usefulness is disputable. In some cases, though, a calcium metabolism disorder could be a valuable tool (i.e. as a marker of extrathoracic sarcoidosis). Although sarcoidosis does not cause a decrease in bone mineral density, increased incidence of vertebral deformities is noted. Despite increasing knowledge about calcium homeostasis disorders in patients with sarcoidosis, there is still a need for clear guidelines regarding calcium and vitamin D supplementation in these patients.</p></abstract><kwd-group><kwd>Sarcoidosis</kwd><kwd>calcium</kwd><kwd>vitamin D</kwd><kwd>hypercalcemia</kwd><kwd>hypercalciuria</kwd><kwd>calcitriol</kwd><kwd>1,25(OH)<sub>2</sub>D<sub>3</sub></kwd><kwd>25(OH)D<sub>3</sub></kwd></kwd-group><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section1-1479973119878713"><title>Introduction</title><p>Calcium metabolism in the human body is tightly regulated. Although many of the mechanisms of control are still not fully described, the present state of knowledge shows that they are far more complicated than the already known parathyroid hormone—vitamin D feedback loop (<xref ref-type="fig" rid="fig1-1479973119878713">Figure 1</xref>). The endocrine activity of osteoblasts and osteoclasts, creating a fibroblast growth factor 23-vitamin D axis, seems to be just as important.<sup><xref rid="bibr1-1479973119878713" ref-type="bibr">1</xref>,<xref rid="bibr2-1479973119878713" ref-type="bibr">2</xref></sup></p><fig id="fig1-1479973119878713" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Selected aspects of human calcium homeostasis.</p></caption><graphic xlink:href="10.1177_1479973119878713-fig1"></graphic></fig><p>The majority of hypercalcemia cases in sarcoidosis are explained by the overproduction of 1,25(OH)<sub>2</sub>D<sub>3</sub> (calcitriol) by activated macrophages. Despite quite convincing evidence supporting this hypothesis, some questions have yet to be completely answered. Moreover, some recent studies suggest that vitamin D supplementation may improve not only calcium homeostasis but also the course of sarcoidosis.<sup><xref rid="bibr3-1479973119878713" ref-type="bibr">3</xref></sup> Naturally, many authors are at odds with this opinion and do not recommend cholecalciferol supplementation in patients with sarcoidosis. Still, it is unknown what factors predispose to calcium homeostasis disorders and how its occurrence changes the outcome. Those, among many other doubts, encouraged us to create a summary and analysis of the knowledge connected with this subject.</p><p>In the context of sarcoidosis, vitamin D and its turnover are interesting because of its important role in the regulation of the immune system and the process of granulomatous inflammation. It is now known that 1-α-hydroxylase expression is present in many tissues. However, only hydroxylation in kidneys, activated macrophages, and the placenta can influence plasma 1,25(OH)<sub>2</sub>D<sub>3</sub> levels.<sup><xref rid="bibr4-1479973119878713" ref-type="bibr">4</xref></sup> It has been shown that calcitriol inhibits the production of (interferon gamma ) INF-γ, lymphotoxin, interleukin 2 (IL-2), and proliferation of certain T-lymphocyte subpopulations.<sup><xref rid="bibr5-1479973119878713" ref-type="bibr">5</xref><xref rid="bibr6-1479973119878713" ref-type="bibr"></xref>–<xref rid="bibr7-1479973119878713" ref-type="bibr">7</xref></sup> A murine model has also proven that calcitriol inhibits IL-6 and tumor necrosis factor alpha (TNF-α) production by lipopolysaccharide (LPS)-stimulated monocytes and macrophages.<sup><xref rid="bibr8-1479973119878713" ref-type="bibr">8</xref></sup> In vitro studies have shown that 1,25(OH)<sub>2</sub>D<sub>3</sub> stimulates monocyte proliferation, differentiation, and transformation into epithelioid cells.<sup><xref rid="bibr9-1479973119878713" ref-type="bibr">9</xref></sup> On the other hand, it inhibits macrophage differentiation into dendritic cells and inhibits dendritic cell maturation, simultaneously stimulating their apoptosis (<xref ref-type="fig" rid="fig2-1479973119878713">Figure 2</xref>).<sup><xref rid="bibr10-1479973119878713" ref-type="bibr">10</xref></sup> Increased expression of TREM-2 (a receptor playing an important role in cell fusion and granuloma formation) on myeloid cells has been found in pulmonary sarcoidosis and, interestingly, compared to subjects with 25(OH)D<sub>3</sub> deficiency (<30 ng/μl), patients with a level between 30 ng/ml and 50 ng/ml had higher total numbers and percentages of TREM2 positive cells in bronchoalveolar lavage fluid.<sup><xref rid="bibr11-1479973119878713" ref-type="bibr">11</xref></sup> Expression of vitamin D receptors has only been found in the alveolar lymphocytes of subjects with sarcoidosis, and not in healthy controls.<sup><xref rid="bibr12-1479973119878713" ref-type="bibr">12</xref>,<xref rid="bibr13-1479973119878713" ref-type="bibr">13</xref></sup> Data about polymorphisms of vitamin D receptor in sarcoidosis are inconsistent. According to Niimi et al., Taq1 polymorphisms seem to be irrelevant. Allele B of Bsm1 alleles is more common in sarcoidosis but does not affect localization nor the course of the disease (101 patients and 105 healthy controls from Japanese population).<sup><xref rid="bibr14-1479973119878713" ref-type="bibr">14</xref></sup> One smaller study (<italic>n</italic> = 35) suggests a higher frequency of allele B in sarcoidosis patients and shows allele B to be present more often in patients with Löfgren syndrome.<sup><xref rid="bibr15-1479973119878713" ref-type="bibr">15</xref></sup> The concentration of vitamin D binding protein is higher in exosomes extracted from bronchoalveolar lavage fluid in patients with sarcoidosis and cerebrospinal fluid from patients with neurosarcoidosis.<sup><xref rid="bibr16-1479973119878713" ref-type="bibr">16</xref>,<xref rid="bibr17-1479973119878713" ref-type="bibr">17</xref></sup> No relationship has been found between vitamin D binding protein different alleles and the incidence of sarcoidosis.<sup><xref rid="bibr18-1479973119878713" ref-type="bibr">18</xref></sup></p><fig id="fig2-1479973119878713" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>It is well-known that vitamin D plays a complex and still not fully understood role in regulation of immune system. Part of its actions can be directly connected with formation of granuloma. Some of them are presented here.</p></caption><graphic xlink:href="10.1177_1479973119878713-fig2"></graphic></fig></sec><sec id="section2-1479973119878713"><title>Epidemiology</title><p>Hypercalcemia occurs in 0.2–4% of the general population. Primary hyperparathyroidism and malignancies are responsible for about 80–90% of all cases.<sup><xref rid="bibr19-1479973119878713" ref-type="bibr">19</xref></sup> Donovan et al. retrospectively analyzed 101 cases of vitamin D3-mediated hypercalcemia and concluded that sarcoidosis was an underlying cause of almost 50% of them. Calcitriol serum concentration above 300 pmol/l was suggestive of another etiology of hypercalcemia.<sup><xref rid="bibr20-1479973119878713" ref-type="bibr">20</xref></sup> Moreover, sarcoidosis is the reason behind about 0.5% of cases of hypercalcemia in patients with a history of malignancies.<sup><xref rid="bibr21-1479973119878713" ref-type="bibr">21</xref></sup> Depending on the studies and population studied, hypercalcemia affects from 7% up to 18% of patients with sarcoidosis.<sup><xref rid="bibr22-1479973119878713" ref-type="bibr">22</xref><xref rid="bibr23-1479973119878713" ref-type="bibr"></xref><xref rid="bibr24-1479973119878713" ref-type="bibr"></xref>–<xref rid="bibr25-1479973119878713" ref-type="bibr">25</xref></sup> In a case–control etiologic study of sarcoidosis (ACCESS), a multicenter prospective study with 736 enrolled patients, incidence of sarcoidosis-associated hypercalcemia was 3.7%.<sup><xref rid="bibr26-1479973119878713" ref-type="bibr">26</xref></sup> However, such a low prevalence could be the result of ethnic composition—44% of the study group consisted of African-Americans. It is suggested that hypercalcemia is less common among these individuals.<sup><xref rid="bibr27-1479973119878713" ref-type="bibr">27</xref>,<xref rid="bibr28-1479973119878713" ref-type="bibr">28</xref></sup> The biggest up-to-date study found, a single-center retrospective study by Baughman et al. (<italic>n</italic> = 1606), reports that hypercalcemia appeared in about 6% of sarcoidosis patients.<sup><xref rid="bibr29-1479973119878713" ref-type="bibr">29</xref></sup> Interestingly, the incidence of hypercalcemia in the Japanese population has been progressively rising between 1974 and 2012.<sup><xref rid="bibr30-1479973119878713" ref-type="bibr">30</xref></sup> No similar reports regarding the European population have been found.</p><p>Evidence about the association between a higher risk of elevated serum calcium level in sarcoidosis and age are inconsistent. Namely, in the ACCESS study, patients >40 years old were identified to be more predisposed to this pathology.<sup><xref rid="bibr26-1479973119878713" ref-type="bibr">26</xref></sup> However Brito-Zerón et al., in a smaller study conducted on the Spanish population, reported patients >65 years old in this context.<sup><xref rid="bibr31-1479973119878713" ref-type="bibr">31</xref></sup> On the other hand, hypercalcemia seems to be more common (prevalence rate about 30%) in children. Examined groups are less numerous but reports are coherent.<sup><xref rid="bibr32-1479973119878713" ref-type="bibr">32</xref><xref rid="bibr33-1479973119878713" ref-type="bibr"></xref>–<xref rid="bibr34-1479973119878713" ref-type="bibr">34</xref></sup></p><p>Association between sex and the incidence of hypercalcemia in sarcoidosis has not been confirmed with some studies showing a higher risk among the male population,<sup><xref rid="bibr22-1479973119878713" ref-type="bibr">22</xref>,<xref rid="bibr26-1479973119878713" ref-type="bibr">26</xref>,<xref rid="bibr31-1479973119878713" ref-type="bibr">31</xref></sup> whereas others show no statistically significant difference between sexes.<sup><xref rid="bibr23-1479973119878713" ref-type="bibr">23</xref></sup> In the mentioned study, Baughman et al. compared a group of about 100 patients with hypercalcemia to 1500 patients with sarcoidosis without calcium metabolism disturbances and failed to find any differences in sex, age, or ethnicity.<sup><xref rid="bibr29-1479973119878713" ref-type="bibr">29</xref></sup> The higher incidence of hypercalcemia in summer months, due to greater UV exposure, has also been suggested.<sup><xref rid="bibr28-1479973119878713" ref-type="bibr">28</xref>,<xref rid="bibr35-1479973119878713" ref-type="bibr">35</xref><xref rid="bibr36-1479973119878713" ref-type="bibr"></xref><xref rid="bibr37-1479973119878713" ref-type="bibr"></xref>–<xref rid="bibr38-1479973119878713" ref-type="bibr">38</xref></sup> A significant risk factor for sarcoidosis-associated hypercalcemia (odds ratio 3.6) found in the ACCESS study (over 470 patients analyzed) is the combination of HLA DRB1*1101 allele and exposure to insecticides.<sup><xref rid="bibr39-1479973119878713" ref-type="bibr">39</xref></sup></p><p>A more frequent sign of dysregulated calcium homeostasis in sarcoidosis comes in the form of hypercalciuria which may affect between 20%<sup><xref rid="bibr40-1479973119878713" ref-type="bibr">40</xref></sup> and even 40%<sup><xref rid="bibr41-1479973119878713" ref-type="bibr">41</xref></sup> of patients. Also, nephrolithiasis is more common in sarcoidosis than in the general population. This complication will occur in 10–14% of patients in the course of the disease. Asymptomatic stones can be found in 2.7% of subjects at the moment of establishing the diagnosis and in approximately 1% of cases, it can be the first symptom of sarcoidosis.<sup><xref rid="bibr42-1479973119878713" ref-type="bibr">42</xref></sup></p></sec><sec id="section3-1479973119878713"><title>The pathophysiology of hypercalcemia in sarcoidosis</title><p>Increased production of 1,25(OH)<sub>2</sub>D<sub>3</sub> is considered to be the main cause of calcium homeostasis disorders in sarcoidosis (<xref ref-type="fig" rid="fig3-1479973119878713">Figure 3</xref>). Increased calcitriol concentration was observed in a few cases of hypercalcemia in patients with sarcoidosis in the late 1970s.<sup><xref rid="bibr43-1479973119878713" ref-type="bibr">43</xref></sup> The discovery of hypercalcemia in combination with elevated calcitriol levels in patients with sarcoidosis and accompanying kidney failure was the proof of its extrarenal production.<sup><xref rid="bibr44-1479973119878713" ref-type="bibr">44</xref>,<xref rid="bibr45-1479973119878713" ref-type="bibr">45</xref></sup> Studies confirmed that homogenate of lymph nodes with sarcoid granuloma produces 1,25(OH)<sub>2</sub>D<sub>3</sub>.<sup><xref rid="bibr46-1479973119878713" ref-type="bibr">46</xref></sup> Adams et al. experimentally proved that pulmonary alveolar macrophages from patients with sarcoidosis can hydroxylate 25(OH)D<sub>3</sub> to 1,25(OH)<sub>2</sub>D<sub>3</sub> and that the process was augmented in cells derived from patients with hypercalcemia.<sup><xref rid="bibr47-1479973119878713" ref-type="bibr">47</xref>,<xref rid="bibr48-1479973119878713" ref-type="bibr">48</xref></sup></p><fig id="fig3-1479973119878713" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Process of 1-α-hydroxylation of 25(OH)D<sub>3</sub> in macrophages is different from the one taking place in kidneys and is not focused on maintaining calcium and phosphate homeostasis but is dependent on immunological processes. The figure shows possible mechanisms of altered vitamin D metabolism and calcium disturbances in sarcoidosis.</p></caption><graphic xlink:href="10.1177_1479973119878713-fig3"></graphic></fig><p>Studies in patients with tuberculosis revealed that macrophages activated via toll-like receptor (TLR) 2/1 present increased expression of 1-α-hydroxylase (CYP27B1) and vitamin D receptor.<sup><xref rid="bibr49-1479973119878713" ref-type="bibr">49</xref></sup> In healthy subjects, pulmonary alveolar macrophages synthesize 1,25(OH)<sub>2</sub>D<sub>3</sub> from 25(OH)D<sub>3</sub> after activation by IFN-γ and LPS. Meanwhile, in pulmonary alveolar macrophages harvested from patients with sarcoidosis (including those without hypercalcemia), this process occurs without previous activation. However, exposure to LPS, IFN-γ, IL-2, or leukotriene C4 induces intensification of 1-α-hydroxylation of 25(OH)D<sub>3</sub>.<sup><xref rid="bibr50-1479973119878713" ref-type="bibr">50</xref><xref rid="bibr51-1479973119878713" ref-type="bibr"></xref><xref rid="bibr52-1479973119878713" ref-type="bibr"></xref>–<xref rid="bibr53-1479973119878713" ref-type="bibr">53</xref></sup> In turn, Lawrence et al. observed hypercalcemia in three out of four patients, who presented the highest concentrations of soluble receptors for IL-2.<sup><xref rid="bibr54-1479973119878713" ref-type="bibr">54</xref></sup> There has also been a case of sarcoidosis exacerbation with the occurrence of hypercalcemia in the course of treatment with IL-2.<sup><xref rid="bibr55-1479973119878713" ref-type="bibr">55</xref></sup> Interestingly, despite overexpression of CYP27B1 in pulmonary alveolar macrophages of patients with lung cancer (irrespective of histopathological type), no differences in calcium, 25(OH)D<sub>3</sub> or 1,25(OH)<sub>2</sub>D<sub>3</sub> levels have been found (in comparison with the control group).<sup><xref rid="bibr56-1479973119878713" ref-type="bibr">56</xref></sup></p><p>It is known that JAK-STAT, NF-κB, and p38 MAPK pathways play a role in the activation of 1-α-hydroxylase. After inhibiting any of them, CYP27B1 expression decreases.<sup><xref rid="bibr57-1479973119878713" ref-type="bibr">57</xref></sup> Calcitrol synthesis is tightly regulated in healthy subjects. However, its synthesis in morbid conditions is not so strictly controlled. This has been noted via a couple of different mechanisms. Firstly, 1-α-hydroxylase from macrophages is less susceptible to feedback inhibition by 1,25(OH)<sub>2</sub>D<sub>3</sub> (this resistance is enhanced by IFN-γ). Secondly, 1,25(OH)<sub>2</sub>D<sub>3</sub> deactivation by 24-hydroxylase is inhibited.<sup><xref rid="bibr50-1479973119878713" ref-type="bibr">50</xref>,<xref rid="bibr52-1479973119878713" ref-type="bibr">52</xref></sup> Because of this, there may be two effects on circulating calcitriol: firstly, it may exceed reference values. Secondly, and more frequently, it may stay within normal range but be inadequate to circulating serum calcium level. Arguments for “inadequate normal” 1,25(OH)<sub>2</sub>D<sub>3</sub> concentration as the main cause of sarcoidosis-associated hypercalcemia are presented and commented in <xref rid="table1-1479973119878713" ref-type="table">Table 1</xref>.</p><table-wrap id="table1-1479973119878713" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Potential evidence supporting phenomenon of “inadequate normal” 1,25(OH)<sub>2</sub>D<sub>3</sub> concentration in patients with sarcoidosis.<sup>a</sup></p></caption><alternatives><graphic xlink:href="10.1177_1479973119878713-table1"></graphic><table frame="hsides" rules="groups"><thead><tr><th colspan="3" rowspan="1">“Inadequate normal” 1,25(OH)<sub>2</sub>D<sub>3</sub> concentration in patients with sarcoidosis</th></tr><tr><th rowspan="1" colspan="1">Observation</th><th rowspan="1" colspan="1">Comment</th><th rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Hypercalcemia accompanied by normal calcitriol level with a decline in its concentration after glucocorticoid treatment</td><td rowspan="1" colspan="1">—</td><td rowspan="1" colspan="1">Unsal et al.,<sup><xref rid="bibr58-1479973119878713" ref-type="bibr">58</xref></sup> Berlin et al.,<sup><xref rid="bibr59-1479973119878713" ref-type="bibr">59</xref></sup> Shrayyef et al.,<sup><xref rid="bibr60-1479973119878713" ref-type="bibr">60</xref></sup> Falk et al.<sup><xref rid="bibr61-1479973119878713" ref-type="bibr">61</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Lack of calcitriol level decrease despite supplementation of calcium in patients with sarcoidosis</td><td rowspan="1" colspan="1">In the healthy subjects, the level of calcitriol should decrease after calcium supplementation</td><td rowspan="1" colspan="1">Basile et al.<sup><xref rid="bibr62-1479973119878713" ref-type="bibr">62</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Increase of 25(OH)D<sub>3</sub> as well as 1,25(OH)<sub>2</sub>D<sub>3</sub> after vitamin D2 supplementation</td><td rowspan="1" colspan="1">In healthy subjects, supplementation influences only 25(OH)D<sub>3</sub> concentration</td><td rowspan="1" colspan="1">Stern et al.<sup><xref rid="bibr63-1479973119878713" ref-type="bibr">63</xref></sup></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-1479973119878713"><p><sup>a</sup>The concentration of 1,25(OH)2D3 in patients with sarcoidosis, even in those with hypercalcemia, usually stays within normal limits. Still, the overproduction of calcitriol is considered to be the leading cause of sarcoidosis-associated hypercalcemia. This leads to the conclusion that there exists a phenomenon of “inadequate normal” 1,25(OH)2D3 concentration in patients with sarcoidosis. The table shows some evidence supporting this theory.</p></fn></table-wrap-foot></table-wrap><p>A positive correlation between 1,25(OH)<sub>2</sub>D<sub>3</sub> level and calcium concentration has been noted in some observational studies (approximately <italic>r</italic> = 0,55).<sup><xref rid="bibr63-1479973119878713" ref-type="bibr">63</xref><xref rid="bibr64-1479973119878713" ref-type="bibr"></xref>–<xref rid="bibr65-1479973119878713" ref-type="bibr">65</xref></sup> However, in one follow-up study with a slightly smaller group (<italic>n</italic> = 39), this relationship has not been confirmed.<sup><xref rid="bibr66-1479973119878713" ref-type="bibr">66</xref></sup></p><p>A few cases of hypercalcemia induced by parathyroid hormone-related protein (PTHrP) have also been described.<sup><xref rid="bibr67-1479973119878713" ref-type="bibr">67</xref><xref rid="bibr68-1479973119878713" ref-type="bibr"></xref>–<xref rid="bibr69-1479973119878713" ref-type="bibr">69</xref></sup> The expression of PTHrP was observed in macrophages and giant cells in the majority of patients with granulomatous diseases, sarcoidosis included. Nevertheless, its circulating serum level hardly ever exceeds normal limits.<sup><xref rid="bibr69-1479973119878713" ref-type="bibr">69</xref><xref rid="bibr70-1479973119878713" ref-type="bibr"></xref><xref rid="bibr71-1479973119878713" ref-type="bibr"></xref>–<xref rid="bibr72-1479973119878713" ref-type="bibr">72</xref></sup> PTHrP expression is stimulated by factors such as LPS, prostaglandin E (PGE), IL-1, transforming growth factor β (TGF-β), and it most likely acts as an anti-inflammatory agent, which would explain its presence in granuloma cells.<sup><xref rid="bibr70-1479973119878713" ref-type="bibr">70</xref></sup></p><p>It is important to remember that sarcoidosis does not exclude other causes of hypercalcemia, beginning with the most common cause: hyperparathyroidism. Such conditions should be excluded during the diagnostic process to enable the introduction of optimal treatment.</p></sec><sec id="section4-1479973119878713"><title>The influence of sarcoidosis and related calcium disturbances on skeletal system</title><p>The influence of sarcoidosis on the skeletal system is mediated by two main etiologies, both of which are risk factors for osteoporosis. Firstly, it is mediated by calcium homeostasis disorders, including frequent 25(OH)D deficiency. Secondly, by treatment with corticosteroids.</p><p>It has been suggested that sarcoidosis itself causes a reduction of bone mineral density (BMD). Heijackmann et al. found that despite higher concentrations of biochemical markers of bone turnover (procollagen type I amino-terminal pro-peptide—PINP and carboxy-terminal cross-linked telopeptide of type I collagen—ICTP), BMD of the hip was normal and did not change in 4-year follow-up.<sup><xref rid="bibr73-1479973119878713" ref-type="bibr">73</xref>,<xref rid="bibr74-1479973119878713" ref-type="bibr">74</xref></sup> Also, Bolland et al., in his 2-year follow-up study of 64 patients with sarcoidosis, failed to find a significant change in BMD in regions such as the lumbar spine, total hip, femoral neck, as well as in total body measurements.<sup><xref rid="bibr75-1479973119878713" ref-type="bibr">75</xref></sup> Two large-group case–control studies did not reveal any increase in a total number of bone fractures caused by sarcoidosis alone.<sup><xref rid="bibr76-1479973119878713" ref-type="bibr">76</xref>,<xref rid="bibr77-1479973119878713" ref-type="bibr">77</xref></sup> However, higher occurrence of fractures and deformations within vertebrae has been noted, including in patients with normal BMD.<sup><xref rid="bibr73-1479973119878713" ref-type="bibr">73</xref>,<xref rid="bibr74-1479973119878713" ref-type="bibr">74</xref>,<xref rid="bibr76-1479973119878713" ref-type="bibr">76</xref>,<xref rid="bibr78-1479973119878713" ref-type="bibr">78</xref></sup> The effectiveness of Vitamin D3 and calcium supplementation in improving BMD in patients with sarcoidosis remains unconfirmed.<sup><xref rid="bibr75-1479973119878713" ref-type="bibr">75</xref>,<xref rid="bibr79-1479973119878713" ref-type="bibr">79</xref></sup> Surprisingly, Saidenberg-Kermanac’h et al., in a cross-sectional study of 142 patients, showed that vitamin D supplementation paradoxically caused BMD reduction and a higher occurrence of bone fractures.<sup><xref rid="bibr78-1479973119878713" ref-type="bibr">78</xref></sup> There is no doubt that the risk of fractures and decreased BMD appear in the course of corticosteroid therapy. Interestingly, population-based studies show that such an effect can be observed only during and up to 3–6 months after the termination of therapy.<sup><xref rid="bibr76-1479973119878713" ref-type="bibr">76</xref>,<xref rid="bibr77-1479973119878713" ref-type="bibr">77</xref></sup> The meta-analyses of available randomized controlled trials (in all patients, not specifically with sarcoidosis) confirm moderate effectiveness of vitamin D supplementation on preventing steroid-induced BMD decline with no statistically significant effect on the incidence of fractures. Treatment with bisphosphonates is more effective in improving BMD and seems to be effective in reducing the risk of vertebral fractures. The most effective agent, however, seems to be teriparatide.<sup><xref rid="bibr80-1479973119878713" ref-type="bibr">80</xref><xref rid="bibr81-1479973119878713" ref-type="bibr"></xref>–<xref rid="bibr82-1479973119878713" ref-type="bibr">82</xref></sup> This is an important issue because there is currently a discussion about supplementation with vitamin D and calcium and its potential in bringing about hypercalcemia and hypercalciuria.<sup><xref rid="bibr36-1479973119878713" ref-type="bibr">36</xref>,<xref rid="bibr62-1479973119878713" ref-type="bibr">62</xref>,<xref rid="bibr83-1479973119878713" ref-type="bibr">83</xref>,<xref rid="bibr84-1479973119878713" ref-type="bibr">84</xref></sup> Two retrospective studies of patients visiting the outpatient clinic stand in opposition to each other. In a cohort analysis of almost 400 patients (randomly chosen, divided in two equal groups) Sodhi and Aldrich showed that the group of patients, who at least once had vitamin D prescribed, had an almost two times higher risk of developing hypercalcemia in a 2-year follow-up.<sup><xref rid="bibr85-1479973119878713" ref-type="bibr">85</xref></sup> On the other hand, Kamphuis et al. did not observe a higher incidence of hypercalcemia in the group using calcium and vitamin D supplementation. In fact, their study showed a protective effect against hypercalcemia (mean dose 400 UI per day) in the group of 70 patients not treated with corticosteroids (39 with supplementation vs. 31 without supplementation).<sup><xref rid="bibr3-1479973119878713" ref-type="bibr">3</xref></sup></p><p>In a randomized trial over 1 year that studied a group of 27 subjects with sarcoidosis taking cholecalciferol supplementation of 50,000 IU/month, there were relevant differences observed in the mean concentration of 25(OH)D<sub>3</sub> ranging from suboptimal average <50 nmol/l to average >75 nmol/l. The authors also observed a small, but statistically significant difference in concentrations of 1,25(OH)<sub>2</sub>D<sub>3</sub>. One patient from the study group developed hypercalcemia.<sup><xref rid="bibr79-1479973119878713" ref-type="bibr">79</xref></sup> Similarly, in a prospective study, in which a group of 16 African-Americans with average 25(OH)D<sub>3</sub> concentration <75 nmol/l were given 50,000 IU/month for 12 weeks, a comparable rise in 25(OH)D<sub>3</sub> occurred with no changes in mean concentrations of Ca and Ca<sup>2+</sup>. Also, no calciuria had been observed. Surprisingly, in the majority of the subjects, 1,25(OH)<sub>2</sub>D<sub>3</sub> concentration decreased by half.<sup><xref rid="bibr86-1479973119878713" ref-type="bibr">86</xref></sup> When supplementation was limited to Ca, increased excretion of calcium in urine was observed, without any effect on calcium and vitamin D metabolites serum concentration.<sup><xref rid="bibr62-1479973119878713" ref-type="bibr">62</xref></sup></p></sec><sec id="section5-1479973119878713"><title>Calcium homeostasis and prognosis</title><p>The association between decreased 25(OH)D<sub>3</sub> level and a more severe course of disease has been described.<sup><xref rid="bibr12-1479973119878713" ref-type="bibr">12</xref></sup> Kiani et al. compared two groups (<italic>n</italic> = 40) of patients suffering from sarcoidosis with one group having 25(OH)D<sub>3</sub> concentration <50 nmol/l and the other >50 nmol/l. They found that 25(OH)D<sub>3</sub> deficiency correlated negatively with lung parenchyma involvement (stages II–IV) and tended to predispose to chronic course of disease in a 2-year follow-up.<sup><xref rid="bibr87-1479973119878713" ref-type="bibr">87</xref></sup> On the other hand, higher mean concentrations of calcitriol were found in patients with active and untreated sarcoidosis.<sup><xref rid="bibr88-1479973119878713" ref-type="bibr">88</xref></sup> Kavathia et al. (in a 59 patient study involving predominantly African-American patients) found a concentration of 1,25(OH)<sub>2</sub>D<sub>3</sub> above 51 pg/ml to be a risk factor for prolonged (>1 year) treatment.<sup><xref rid="bibr89-1479973119878713" ref-type="bibr">89</xref></sup></p><p>The correlation between calcitriol concentration and 67 Ga uptake has not been noted,<sup><xref rid="bibr90-1479973119878713" ref-type="bibr">90</xref></sup> but 25(OH)D<sub>3</sub> concentration correlated negatively with results of a somatostatin receptor scintigraphy.<sup><xref rid="bibr3-1479973119878713" ref-type="bibr">3</xref></sup></p><p>In renal sarcoidosis, a correlation between hypercalcemia and complete response to glucocorticoid treatment has been observed (a retrospective study of 46 patients with biopsy-proven renal sarcoidosis).<sup><xref rid="bibr28-1479973119878713" ref-type="bibr">28</xref></sup> In the observational study performed on 36 Japanese patients, Hamada et al. observed that ionized calcium level above 1.23 mmol/l was a 100% specific indicator for extrapulmonary sarcoidosis.<sup><xref rid="bibr64-1479973119878713" ref-type="bibr">64</xref></sup></p></sec><sec id="section6-1479973119878713"><title>Management</title><p>The management of hypercalcemia depends mostly on the level of calcium. Patients with moderate elevations in serum calcium (12.0–14.0 mg/dl) may develop symptoms when levels rise rapidly. This group of symptomatic patients requires immediate intervention. Intensive treatment is usually necessary when serum calcium concentration exceeds 14 mg/dl. Intravenous rehydration and loop diuretics are the treatment of choice. Bisphosphonates should be given intravenously in case other treatment options are ineffective (<xref ref-type="fig" rid="fig4-1479973119878713">Figure 4</xref>).<sup><xref rid="bibr19-1479973119878713" ref-type="bibr">19</xref></sup></p><fig id="fig4-1479973119878713" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Proposed scheme of sarcoidosis-associated hypercalcemia treatment.</p></caption><graphic xlink:href="10.1177_1479973119878713-fig4"></graphic></fig><p>Corticosteroids are the causal first-line treatment in sarcoidosis-associated hypercalcemia. In vitro studies have confirmed that dexamethasone suppresses calcitriol production in sarcoidosis patients’ pulmonary alveolar macrophages.<sup><xref rid="bibr50-1479973119878713" ref-type="bibr">50</xref></sup> The treatment schedule of an initial 40 mg dose of prednisone followed by a reduction to 20 mg in 1–2 weeks appears to be effective. Further dose reduction should follow within the upcoming weeks. The decrease of serum calcium level usually takes place a week after the onset of treatment, and calcium excretion in urine decreases after approximately 10 days. A lack of response to treatment within 2 weeks may indicate another cause of hypercalcemia.<sup><xref rid="bibr91-1479973119878713" ref-type="bibr">91</xref>,<xref rid="bibr92-1479973119878713" ref-type="bibr">92</xref></sup></p><p>Our clinical observations suggest that in cases of progressive kidney failure, when dual etiology (hypercalcemic and sarcoidosis of kidneys) could not be excluded, IV methylprednisolone was effective. Other drugs successfully (but rarely) used in the treatment of calcium homeostasis disorders are (hydroxy) chloroquine and ketoconazole.<sup><xref rid="bibr93-1479973119878713" ref-type="bibr">93</xref><xref rid="bibr94-1479973119878713" ref-type="bibr"></xref><xref rid="bibr95-1479973119878713" ref-type="bibr"></xref>–<xref rid="bibr96-1479973119878713" ref-type="bibr">96</xref></sup> Both drugs suppress 1-α-hydroxylase and chloroquine additionally stimulates calcitriol deactivation by 24-hydroxylase.<sup><xref rid="bibr50-1479973119878713" ref-type="bibr">50</xref>,<xref rid="bibr93-1479973119878713" ref-type="bibr">93</xref></sup> Infliximab has also proven to be an effective option in sarcoidosis-associated hypercalcemia in cases of toxicity or resistance to corticosteroids and other immunosuppressive drugs.<sup><xref rid="bibr97-1479973119878713" ref-type="bibr">97</xref>,<xref rid="bibr98-1479973119878713" ref-type="bibr">98</xref></sup> It is worth mentioning that sodium cellulose phosphate and flurbiprofen have been administered in the past for the treatment of hypercalcemia and nephrocalcinosis.<sup><xref rid="bibr99-1479973119878713" ref-type="bibr">99</xref><xref rid="bibr100-1479973119878713" ref-type="bibr"></xref>–<xref rid="bibr101-1479973119878713" ref-type="bibr">101</xref></sup></p><p>In the case of hypercalciuria, thiazide diuretics are contraindicated due to their potential to induce hypercalcemia. Some authors suggest a low-calcium diet, but studies seem to question this recommendation. Hypercalciuria persisted in 30% of patients despite calcium restriction in their diet. Further, the use of pharmacotherapy to limit calcium absorption did not improve calcium concentration control.<sup><xref rid="bibr102-1479973119878713" ref-type="bibr">102</xref>,<xref rid="bibr103-1479973119878713" ref-type="bibr">103</xref></sup> In a 4-year observational study, a lower incidence of nephrolithiasis was observed in patients with higher dietary calcium intake, which may be related to inhibition of oxalates absorption. While renal calculi in patients with sarcoidosis consist mainly of calcium oxalates, calcium restriction in the diet may produce unexpectedly harmful results.<sup><xref rid="bibr104-1479973119878713" ref-type="bibr">104</xref><xref rid="bibr105-1479973119878713" ref-type="bibr"></xref>–<xref rid="bibr106-1479973119878713" ref-type="bibr">106</xref></sup></p></sec><sec sec-type="conclusions" id="section7-1479973119878713"><title>Conclusions</title><p>Sarcoidosis-associated hypercalcemia is quite a common problem as it affects about 6% of patients. It is also one of the indications to introduce pharmacotherapy with steroids. Its pathophysiology appears to be quite well explained. Although it seems logical that vitamin D metabolites should be good tools for assessing disease activity, clinically it is not that simple. Increased conversion of 25(OH)D<sub>3</sub> to calcitriol suggests that perhaps the ratio of 25(OH)D<sub>3</sub> to 1,25(OH)<sub>2</sub>D<sub>3</sub> could be more adequate than absolute values. One study confirms this theory.<sup><xref rid="bibr107-1479973119878713" ref-type="bibr">107</xref></sup></p><p>Despite our increasing knowledge about calcium homeostasis disorders in patients with sarcoidosis, there is still a need for clear guidelines regarding calcium and Vitamin D supplementation. Papers concerning this problem are inconclusive. It appears that supplementation increases the risk of hypercalcemia but only in a certain group of patients. Nevertheless, indications for supplementation seem to be limited, as it is probably ineffective in preventing steroid-induced osteoporosis fractures. An improvement in the course of sarcoidosis in patients with corrected vitamin D insufficiency is a tempting perspective, but more evidence is needed.</p><p>Management of sarcoidosis-associated hypercalcemia should start with excluding other causes of elevated calcium levels. Intensive hydration coupled with loop diuretics (if needed, especially in the elderly and patients with heart failure) should be introduced to reduce hypercalcemia and prevent its acute complication. Corticosteroids should be introduced to remove the cause of calcium metabolism disturbance. Oral treatment with prednisone (doses of 0.5–1 mg/kg a day) is sufficient. In cases of progressive kidney failure, when dual etiology (hypercalcemic and sarcoidosis of kidneys) could not be excluded, IV methylprednisolone would be used.</p><p>The complex action of vitamin D on the immune system coupled with the pathophysiology of granulomatous inflammation seen in sarcoidosis could possibly provide new therapeutic targets in the future.</p></sec></body><back><fn-group><fn fn-type="COI-statement" id="fn1-1479973119878713"><p><bold>Declaration of conflicting interests:</bold> The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn><fn fn-type="financial-disclosure" id="fn2-1479973119878713"><p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The costs of this study were defrayed from regular finances of the Department of Pneumology and Allergy of Medical University of Lodz, Poland (503/1-151-03/503-11-001-19-00).</p></fn><fn fn-type="other" id="fn3-1479973119878713"><p><bold>ORCID iD:</bold> Adam J Białas <inline-graphic xlink:href="10.1177_1479973119878713-img1.jpg"></inline-graphic><ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-3501-167X">https://orcid.org/0000-0002-3501-167X</ext-link></p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-1479973119878713"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blau</surname><given-names>JE</given-names></name><name><surname>Collins</surname><given-names>MT</given-names></name></person-group><article-title>The PTH-vitamin D-FGF23 axis</article-title>. <source>Rev Endocr Metab Disord</source><year>2015</year>; <volume>16</volume>: <fpage>165</fpage>–<lpage>174</lpage>.<pub-id pub-id-type="pmid">26296372</pub-id></mixed-citation></ref><ref id="bibr2-1479973119878713"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokota</surname><given-names>H</given-names></name><name><surname>Raposo</surname><given-names>JF</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Evaluation of the role of FGF23 in mineral metabolism</article-title>. <source>Gene Regul Syst Biol</source><year>2009</year>; <volume>3</volume>: <fpage>131</fpage>–<lpage>142</lpage>.</mixed-citation></ref><ref id="bibr3-1479973119878713"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamphuis</surname><given-names>LS</given-names></name><name><surname>Bonte-Mineur</surname><given-names>F</given-names></name><name><surname>van Laar</surname><given-names>JA</given-names></name></person-group>, <etal>et al.</etal><article-title>Calcium and vitamin D in sarcoidosis: is supplementation safe?</article-title><source>J Bone Miner Res</source><year>2014</year>; <volume>29</volume>: <fpage>2498</fpage>–<lpage>2503</lpage>.<pub-id pub-id-type="pmid">24753153</pub-id></mixed-citation></ref><ref id="bibr4-1479973119878713"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>JS</given-names></name><name><surname>Hewison</surname><given-names>M</given-names></name></person-group><article-title>Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase</article-title>. <source>Arch Biochem Biophys</source><year>2012</year>; <volume>523</volume>: <fpage>95</fpage>–<lpage>102</lpage>.<pub-id pub-id-type="pmid">22446158</pub-id></mixed-citation></ref><ref id="bibr5-1479973119878713"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rottoli</surname><given-names>P</given-names></name><name><surname>Muscettola</surname><given-names>M</given-names></name><name><surname>Grasso</surname><given-names>G</given-names></name></person-group>, <etal>et al.</etal><article-title>Impaired interferon-gamma production by peripheral blood mononuclear cells and effects of calcitriol in pulmonary sarcoidosis</article-title>. <source>Sarcoidosis</source><year>1993</year>; <volume>10</volume>: <fpage>108</fpage>–<lpage>114</lpage>.<pub-id pub-id-type="pmid">8140295</pub-id></mixed-citation></ref><ref id="bibr6-1479973119878713"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muscettola</surname><given-names>M</given-names></name><name><surname>Grasso</surname><given-names>G</given-names></name></person-group><article-title>Effect of 1,25-dihydroxyvitamin D3 on interferon gamma production in vitro</article-title>. <source>Immunol Lett</source><year>1988</year>; <volume>17</volume>: <fpage>121</fpage>–<lpage>124</lpage>.<pub-id pub-id-type="pmid">3129369</pub-id></mixed-citation></ref><ref id="bibr7-1479973119878713"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>K</given-names></name><name><surname>Bendtzen</surname><given-names>K.</given-names></name></person-group><article-title>Inhibition of human T lymphocyte proliferation and cytokine production by 1,25-dihydroxyvitamin D3. Differential effects on CD45RA+ and CD45R0+ cells</article-title>. <source>Autoimmunity</source><year>1992</year>; <volume>14</volume>: <fpage>37</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">1299346</pub-id></mixed-citation></ref><ref id="bibr8-1479973119878713"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Leung</surname><given-names>DYM</given-names></name><name><surname>Richers</surname><given-names>BN</given-names></name></person-group>, <etal>et al.</etal><article-title>Vitamin D inhibits monocyte/macrophage pro-inflammatory cytokine production by targeting mitogen-activated protein kinase phosphatase 1</article-title>. <source>J Immunol Baltim Md 1950</source><year>2012</year>; <volume>188</volume>: <fpage>2127</fpage>–<lpage>2135</lpage>.</mixed-citation></ref><ref id="bibr9-1479973119878713"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohta</surname><given-names>M</given-names></name><name><surname>Okabe</surname><given-names>T</given-names></name><name><surname>Ozawa</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>In vitro formation of macrophage-epithelioid cells and multinucleated giant cells by 1 alpha,25-dihydroxy vitamin D3 from human circulating monocytes</article-title>. <source>Ann N Y Acad Sci</source><year>1986</year>; <volume>465</volume>: <fpage>211</fpage>–<lpage>220</lpage>.<pub-id pub-id-type="pmid">3460380</pub-id></mixed-citation></ref><ref id="bibr10-1479973119878713"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penna</surname><given-names>G</given-names></name><name><surname>Adorini</surname><given-names>L.</given-names></name></person-group><article-title>1α,25-Dihydroxyvitamin d3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation</article-title>. <source>J Immunol</source><year>2000</year>; <volume>164</volume>: <fpage>2405</fpage>–<lpage>2411</lpage>.<pub-id pub-id-type="pmid">10679076</pub-id></mixed-citation></ref><ref id="bibr11-1479973119878713"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bucova</surname><given-names>M</given-names></name><name><surname>Suchankova</surname><given-names>M</given-names></name><name><surname>Tibenska</surname><given-names>E</given-names></name></person-group>, <etal>et al.</etal><article-title>TREM-2 receptor expression increases with 25(OH)D vitamin serum levels in patients with pulmonary sarcoidosis</article-title>. <source>Mediators Inflamm</source><year>2015</year><comment>Epub ahead of print 2015</comment><comment>DOI: 10.1155/2015/181986</comment>.</mixed-citation></ref><ref id="bibr12-1479973119878713"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barna</surname><given-names>BP</given-names></name><name><surname>Culver</surname><given-names>DA</given-names></name><name><surname>Kanchwala</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Alveolar macrophage cathelicidin deficiency in severe sarcoidosis</article-title>. <source>J Innate Immun</source><year>2012</year>; <volume>4</volume>: <fpage>569</fpage>–<lpage>578</lpage>.<pub-id pub-id-type="pmid">22759465</pub-id></mixed-citation></ref><ref id="bibr13-1479973119878713"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biyoudi-Vouenze</surname><given-names>R</given-names></name><name><surname>Cadranel</surname><given-names>J</given-names></name><name><surname>Valeyre</surname><given-names>D</given-names></name></person-group>, <etal>et al.</etal><article-title>Expression of 1,25(OH)<sub>2</sub>D<sub>3</sub> receptors on alveolar lymphocytes from patients with pulmonary granulomatous diseases</article-title>. <source>Am Rev Respir Dis</source><year>1991</year>; <volume>143</volume>: <fpage>1376</fpage>–<lpage>1380</lpage>.<pub-id pub-id-type="pmid">1646583</pub-id></mixed-citation></ref><ref id="bibr14-1479973119878713"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niimi</surname><given-names>T</given-names></name><name><surname>Tomita</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Vitamin D receptor gene polymorphism in patients with sarcoidosis</article-title>. <source>Am J Respir Crit Care Med</source><year>1999</year>; <volume>160</volume>: <fpage>1107</fpage>–<lpage>1109</lpage>.<pub-id pub-id-type="pmid">10508794</pub-id></mixed-citation></ref><ref id="bibr15-1479973119878713"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petkovic</surname><given-names>TR</given-names></name><name><surname>Pejcic</surname><given-names>T</given-names></name><name><surname>Marinkovic</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>The role of vitamin D receptor Bsm1 polymorphism in the course of sarcoidosis</article-title>. <source>Eur Respir J</source><year>2017</year>; <volume>50</volume>: <fpage>PA980</fpage>.</mixed-citation></ref><ref id="bibr16-1479973119878713"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taibi</surname><given-names>L</given-names></name><name><surname>Boursier</surname><given-names>C</given-names></name><name><surname>Clodic</surname><given-names>G</given-names></name></person-group>, <etal>et al.</etal><article-title>Search for biomarkers of neurosarcoidosis by proteomic analysis of cerebrospinal fluid</article-title>. <source>Ann Biol Clin (Paris)</source><year>2017</year>; <volume>75</volume>: <fpage>393</fpage>–<lpage>402</lpage>.<pub-id pub-id-type="pmid">28751284</pub-id></mixed-citation></ref><ref id="bibr17-1479973119878713"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Bravo</surname><given-names>M-J</given-names></name><name><surname>Wahlund</surname><given-names>CJE</given-names></name><name><surname>Qazi</surname><given-names>KR</given-names></name></person-group>, <etal>et al.</etal><article-title>Pulmonary sarcoidosis is associated with exosomal vitamin D-binding protein and inflammatory molecules</article-title>. <source>J Allergy Clin Immunol</source><year>2017</year>; <volume>139</volume>: <fpage>1186</fpage>–<lpage>1194</lpage>.<pub-id pub-id-type="pmid">27566455</pub-id></mixed-citation></ref><ref id="bibr18-1479973119878713"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milman</surname><given-names>N</given-names></name><name><surname>Thymann</surname><given-names>M</given-names></name><name><surname>Graudal</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>Plasma vitamin D-binding protein (GC) factors, immunoglobulin G heavy chain (GM) allotypes and immunoglobulin kappa light chain (KM1) allotype in patients with sarcoidosis and in healthy control subjects</article-title>. <source>Sarcoidosis Vasc</source><year>2002</year>; <volume>19</volume>: <fpage>97</fpage>–<lpage>100</lpage>.</mixed-citation></ref><ref id="bibr19-1479973119878713"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renaghan</surname><given-names>AD</given-names></name><name><surname>Rosner</surname><given-names>MH</given-names></name></person-group><article-title>Hypercalcemia: etiology and management</article-title>. <source>Nephrol Dial Transplant</source><year>2018</year>; <volume>33</volume>: <fpage>549</fpage>–<lpage>551</lpage>.</mixed-citation></ref><ref id="bibr20-1479973119878713"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donovan</surname><given-names>PJ</given-names></name><name><surname>Sundac</surname><given-names>L</given-names></name><name><surname>Pretorius</surname><given-names>CJ</given-names></name></person-group>, <etal>et al.</etal><article-title>Calcitriol-mediated hypercalcemia: causes and course in 101 patients</article-title>. <source>J Clin Endocrinol Metab</source><year>2013</year>; <volume>98</volume>: <fpage>4023</fpage>–<lpage>4029</lpage>.<pub-id pub-id-type="pmid">23979953</pub-id></mixed-citation></ref><ref id="bibr21-1479973119878713"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soyfoo</surname><given-names>MS</given-names></name><name><surname>Brenner</surname><given-names>K</given-names></name><name><surname>Paesmans</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence</article-title>. <source>Support Care Cancer</source><year>2013</year>; <volume>21</volume>: <fpage>1415</fpage>–<lpage>1419</lpage>.<pub-id pub-id-type="pmid">23229654</pub-id></mixed-citation></ref><ref id="bibr22-1479973119878713"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morimoto</surname><given-names>T</given-names></name><name><surname>Azuma</surname><given-names>A</given-names></name><name><surname>Abe</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Epidemiology of sarcoidosis in Japan</article-title>. <source>Eur Respir J</source><year>2008</year>; <volume>31</volume>: <fpage>372</fpage>–<lpage>379</lpage>.<pub-id pub-id-type="pmid">17959635</pub-id></mixed-citation></ref><ref id="bibr23-1479973119878713"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ungprasert</surname><given-names>P</given-names></name><name><surname>Crowson</surname><given-names>CS</given-names></name><name><surname>Matteson</surname><given-names>EL</given-names></name></person-group><article-title>Influence of gender on epidemiology and clinical manifestations of sarcoidosis: a population-based retrospective cohort study 1976-2013</article-title>. <source>Lung</source><year>2017</year>; <volume>195</volume>: <fpage>87</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">27709291</pub-id></mixed-citation></ref><ref id="bibr24-1479973119878713"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>DG</given-names></name><name><surname>Neville</surname><given-names>E</given-names></name><name><surname>Siltzbach</surname><given-names>LE</given-names></name></person-group><article-title>A worldwide review of sarcoidosis</article-title>. <source>Ann N Y Acad Sci</source><year>1976</year>; <volume>278</volume>: <fpage>321</fpage>–<lpage>334</lpage>.<pub-id pub-id-type="pmid">1067017</pub-id></mixed-citation></ref><ref id="bibr25-1479973119878713"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Studdy</surname><given-names>PR</given-names></name><name><surname>Bird</surname><given-names>R</given-names></name><name><surname>Neville</surname><given-names>E</given-names></name></person-group>, <etal>et al.</etal><article-title>Biochemical findings in sarcoidosis</article-title>. <source>J Clin Pathol</source><year>1980</year>; <volume>33</volume>: <fpage>528</fpage>–<lpage>533</lpage>.<pub-id pub-id-type="pmid">6249857</pub-id></mixed-citation></ref><ref id="bibr26-1479973119878713"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baughman</surname><given-names>RP</given-names></name><name><surname>Teirstein</surname><given-names>AS</given-names></name><name><surname>Judson</surname><given-names>MA</given-names></name></person-group>, <etal>et al.</etal><article-title>Clinical characteristics of patients in a case control study of sarcoidosis</article-title>. <source>Am J Respir Crit Care Med</source><year>2001</year>; <volume>164</volume>: <fpage>1885</fpage>–<lpage>1889</lpage>.<pub-id pub-id-type="pmid">11734441</pub-id></mixed-citation></ref><ref id="bibr27-1479973119878713"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Feldman</surname><given-names>C</given-names></name><name><surname>Reyneke</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Sarcoidosis in Johannesburg – a comparative study of black and white patients</article-title>. <source>South Afr Med J</source><year>1991</year>; <volume>80</volume>: <fpage>423</fpage>–<lpage>427</lpage>.</mixed-citation></ref><ref id="bibr28-1479973119878713"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahévas</surname><given-names>M</given-names></name><name><surname>Lescure</surname><given-names>FX</given-names></name><name><surname>Boffa</surname><given-names>J-J</given-names></name></person-group>, <etal>et al.</etal><article-title>Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients</article-title>. <source>Medicine (Baltimore)</source><year>2009</year>; <volume>88</volume>: <fpage>98</fpage>.<pub-id pub-id-type="pmid">19282700</pub-id></mixed-citation></ref><ref id="bibr29-1479973119878713"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baughman</surname><given-names>RP</given-names></name><name><surname>Janovcik</surname><given-names>J</given-names></name><name><surname>Ray</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Calcium and vitamin D metabolism in sarcoidosis</article-title>. <source>Sarcoidosis Vasc</source><year>2013</year>; <volume>30</volume>: <fpage>113</fpage>–<lpage>120</lpage>.</mixed-citation></ref><ref id="bibr30-1479973119878713"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawahata</surname><given-names>M</given-names></name><name><surname>Sugiyama</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>Age-related and historical changes in the clinical characteristics of sarcoidosis in Japan</article-title>. <source>Respir Med</source><year>2015</year>; <volume>109</volume>: <fpage>272</fpage>–<lpage>278</lpage>.<pub-id pub-id-type="pmid">25613109</pub-id></mixed-citation></ref><ref id="bibr31-1479973119878713"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brito-Zerón</surname><given-names>P</given-names></name><name><surname>Sellarés</surname><given-names>J</given-names></name><name><surname>Bosch</surname><given-names>X</given-names></name></person-group>, <etal>et al.</etal><article-title>Epidemiologic patterns of disease expression in sarcoidosis: age, gender and ethnicity-related differences</article-title>. <source>Clin Exp Rheumatol</source><year>2016</year>; <volume>34</volume>: <fpage>380</fpage>–<lpage>388</lpage>.<pub-id pub-id-type="pmid">27050339</pub-id></mixed-citation></ref><ref id="bibr32-1479973119878713"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abernathy</surname><given-names>RS</given-names></name></person-group><article-title>Childhood sarcoidosis in Arkansas</article-title>. <source>South Med J</source><year>1985</year>; <volume>78</volume>: <fpage>435</fpage>–<lpage>439</lpage>.<pub-id pub-id-type="pmid">3983664</pub-id></mixed-citation></ref><ref id="bibr33-1479973119878713"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>AL</given-names></name><name><surname>Milman</surname><given-names>N</given-names></name><name><surname>Byg</surname><given-names>KE</given-names></name></person-group><article-title>Childhood sarcoidosis in Denmark 1979–1994: incidence, clinical features and laboratory results at presentation in 48 children</article-title>. <source>Acta Paediatr Oslo Nor</source><volume>1992</volume><year>2004</year>; <issue>93</issue>: <fpage>30</fpage>–<lpage>36</lpage>.</mixed-citation></ref><ref id="bibr34-1479973119878713"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>PJ</given-names></name><name><surname>Olinsky</surname><given-names>A</given-names></name></person-group><article-title>Sarcoidosis in children</article-title>. <source>Aust Paediatr J</source><year>1986</year>; <volume>22</volume>: <fpage>291</fpage>–<lpage>293</lpage>.<pub-id pub-id-type="pmid">3566675</pub-id></mixed-citation></ref><ref id="bibr35-1479973119878713"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>MJ</given-names></name><name><surname>Hey</surname><given-names>GB</given-names></name></person-group><article-title>Recurring ‘red eyes’ due to seasonal hypercalcaemia</article-title>. <source>Postgrad Med J</source><year>1976</year>; <volume>52</volume>: <fpage>86</fpage>–<lpage>89</lpage>.</mixed-citation></ref><ref id="bibr36-1479973119878713"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papapoulos</surname><given-names>SE</given-names></name><name><surname>Clemens</surname><given-names>TL</given-names></name><name><surname>Fraher</surname><given-names>LJ</given-names></name></person-group>, <etal>et al.</etal><article-title>1, 25-dihydroxycholecalciferol in the pathogenesis of the hypercalcaemia of sarcoidosis</article-title>. <source>Lancet Lond Engl</source><year>1979</year>; <volume>1</volume>: <fpage>627</fpage>–<lpage>630</lpage>.</mixed-citation></ref><ref id="bibr37-1479973119878713"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cronin</surname><given-names>CC</given-names></name><name><surname>Dinneen</surname><given-names>SF</given-names></name><name><surname>O’Mahony</surname><given-names>MS</given-names></name></person-group>, <etal>et al.</etal><article-title>Precipitation of hypercalcaemia in sarcoidosis by foreign sun holidays: report of four cases</article-title>. <source>Postgrad Med J</source><year>1990</year>; <volume>66</volume>: <fpage>307</fpage>–<lpage>309</lpage>.<pub-id pub-id-type="pmid">2385556</pub-id></mixed-citation></ref><ref id="bibr38-1479973119878713"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiemeyer</surname><given-names>A</given-names></name><name><surname>Schwarze</surname><given-names>EW</given-names></name><name><surname>Mathias</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Acute kidney failure in a recurrence of sarcoidosis at the height of summer</article-title>. <source>Dtsch Med Wochenschr</source><volume>1946</volume><year>1996</year>; <issue>121</issue>: <fpage>165</fpage>–<lpage>168</lpage>.</mixed-citation></ref><ref id="bibr39-1479973119878713"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossman</surname><given-names>MD</given-names></name><name><surname>Thompson</surname><given-names>B</given-names></name><name><surname>Frederick</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>HLA and environmental interactions in sarcoidosis</article-title>. <source>Sarcoidosis Vasc</source><year>2008</year>; <volume>25</volume>: <fpage>125</fpage>–<lpage>132</lpage>.</mixed-citation></ref><ref id="bibr40-1479973119878713"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lancina Martín</surname><given-names>JA</given-names></name><name><surname>García Freire</surname><given-names>C</given-names></name><name><surname>Busto Castañón</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal><article-title>Sarcoidosis and urolithiasis</article-title>. <source>Arch Esp Urol</source><year>1995</year>; <volume>48</volume>: <fpage>234</fpage>–<lpage>239</lpage>.<pub-id pub-id-type="pmid">7755429</pub-id></mixed-citation></ref><ref id="bibr41-1479973119878713"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iannuzzi</surname><given-names>MC</given-names></name><name><surname>Rybicki</surname><given-names>BA</given-names></name><name><surname>Teirstein</surname><given-names>AS</given-names></name></person-group><article-title>Sarcoidosis</article-title>. <source>N Engl J Med</source><year>2007</year>; <volume>357</volume>: <fpage>2153</fpage>–<lpage>2165</lpage>.<pub-id pub-id-type="pmid">18032765</pub-id></mixed-citation></ref><ref id="bibr42-1479973119878713"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berliner</surname><given-names>AR</given-names></name><name><surname>Haas</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>MJ</given-names></name></person-group><article-title>Sarcoidosis: the nephrologist’s perspective</article-title>. <source>Am J Kidney Dis</source><year>2006</year>; <volume>48</volume>: <fpage>856</fpage>–<lpage>870</lpage>.<pub-id pub-id-type="pmid">17060009</pub-id></mixed-citation></ref><ref id="bibr43-1479973119878713"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>NH</given-names></name><name><surname>Stern</surname><given-names>PH</given-names></name><name><surname>Pantzer</surname><given-names>E</given-names></name></person-group>, <etal>et al.</etal><article-title>Evidence that increased circulating 1 alpha, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis</article-title>. <source>J Clin Invest</source><year>1979</year>; <volume>64</volume>: <fpage>218</fpage>–<lpage>225</lpage>.<pub-id pub-id-type="pmid">312811</pub-id></mixed-citation></ref><ref id="bibr44-1479973119878713"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbour</surname><given-names>GL</given-names></name><name><surname>Coburn</surname><given-names>JW</given-names></name><name><surname>Slatopolsky</surname><given-names>E</given-names></name></person-group>, <etal>et al.</etal><article-title>Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D</article-title>. <source>N Engl J Med</source><year>1981</year>; <volume>305</volume>: <fpage>440</fpage>–<lpage>443</lpage>.<pub-id pub-id-type="pmid">6894783</pub-id></mixed-citation></ref><ref id="bibr45-1479973119878713"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maesaka</surname><given-names>JK</given-names></name><name><surname>Batuman</surname><given-names>V</given-names></name><name><surname>Pablo</surname><given-names>NC</given-names></name></person-group>, <etal>et al.</etal><article-title>Elevated 1,25-dihydroxyvitamin D levels: occurrence with sarcoidosis with end-stage renal disease</article-title>. <source>Arch Intern Med</source><year>1982</year>; <volume>142</volume>: <fpage>1206</fpage>–<lpage>1207</lpage>.<pub-id pub-id-type="pmid">6896430</pub-id></mixed-citation></ref><ref id="bibr46-1479973119878713"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>RS</given-names></name><name><surname>Frankel</surname><given-names>T</given-names></name><name><surname>Chan</surname><given-names>YL</given-names></name></person-group>, <etal>et al.</etal><article-title>Vitamin D conversion by sarcoid lymph node homogenate</article-title>. <source>Ann Intern Med</source><year>1984</year>; <volume>100</volume>: <fpage>59</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">6546329</pub-id></mixed-citation></ref><ref id="bibr47-1479973119878713"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>JS</given-names></name><name><surname>Sharma</surname><given-names>OP</given-names></name><name><surname>Gacad</surname><given-names>MA</given-names></name></person-group>, <etal>et al.</etal><article-title>Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis</article-title>. <source>J Clin Invest</source><year>1983</year>; <volume>72</volume>: <fpage>1856</fpage>–<lpage>1860</lpage>.<pub-id pub-id-type="pmid">6688814</pub-id></mixed-citation></ref><ref id="bibr48-1479973119878713"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>JS</given-names></name><name><surname>Singer</surname><given-names>FR</given-names></name><name><surname>Gacad</surname><given-names>MA</given-names></name></person-group>, <etal>et al.</etal><article-title>Isolation and structural identification of 1,25-dihydroxyvitamin D3 produced by cultured alveolar macrophages in sarcoidosis</article-title>. <source>J Clin Endocrinol Metab</source><year>1985</year>; <volume>60</volume>: <fpage>960</fpage>–<lpage>966</lpage>.<pub-id pub-id-type="pmid">2984238</pub-id></mixed-citation></ref><ref id="bibr49-1479973119878713"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>JS</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Chun</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Substrate and enzyme trafficking as a means of regulating 1,25-dihydroxyvitamin D synthesis and action: the human innate immune response</article-title>. <source>J Bone Miner Res</source><year>2007</year>; <volume>22</volume>(<issue>Suppl 2</issue>): <fpage>V20</fpage>–<lpage>V24</lpage>.<pub-id pub-id-type="pmid">18290716</pub-id></mixed-citation></ref><ref id="bibr50-1479973119878713"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichel</surname><given-names>H</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name><name><surname>Barbers</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Regulation of 1,25-dihydroxyvitamin D3 production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis</article-title>. <source>J Clin Endocrinol Metab</source><year>1987</year>; <volume>65</volume>: <fpage>1201</fpage>–<lpage>1209</lpage>.<pub-id pub-id-type="pmid">3119653</pub-id></mixed-citation></ref><ref id="bibr51-1479973119878713"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>JS</given-names></name><name><surname>Modlin</surname><given-names>RL</given-names></name><name><surname>Diz</surname><given-names>MM</given-names></name></person-group>, <etal>et al.</etal><article-title>Potentiation of the macrophage 25-hydroxyvitamin D-1-hydroxylation reaction by human tuberculous pleural effusion fluid</article-title>. <source>J Clin Endocrinol Metab</source><year>1989</year>; <volume>69</volume>: <fpage>457</fpage>–<lpage>460</lpage>.<pub-id pub-id-type="pmid">2502557</pub-id></mixed-citation></ref><ref id="bibr52-1479973119878713"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dusso</surname><given-names>AS</given-names></name><name><surname>Kamimura</surname><given-names>S</given-names></name><name><surname>Gallieni</surname><given-names>M</given-names></name></person-group><article-title>, et al. gamma-Interferon-induced resistance to 1,25-(OH)<sub>2</sub>D<sub>3</sub> in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses</article-title>. <source>J Clin Endocrinol Metab</source><year>1997</year>; <volume>82</volume>: <fpage>2222</fpage>–<lpage>2232</lpage>.<pub-id pub-id-type="pmid">9215298</pub-id></mixed-citation></ref><ref id="bibr53-1479973119878713"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>JS</given-names></name><name><surname>Gacad</surname><given-names>MA</given-names></name><name><surname>Diz</surname><given-names>MM</given-names></name></person-group>, <etal>et al.</etal><article-title>A role for endogenous arachidonate metabolites in the regulated expression of the 25-hydroxyvitamin D-1-hydroxylation reaction in cultured alveolar macrophages from patients with sarcoidosis</article-title>. <source>J Clin Endocrinol Metab</source><year>1990</year>; <volume>70</volume>: <fpage>595</fpage>–<lpage>600</lpage>.<pub-id pub-id-type="pmid">2106525</pub-id></mixed-citation></ref><ref id="bibr54-1479973119878713"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>EC</given-names></name><name><surname>Berger</surname><given-names>MB</given-names></name><name><surname>Brousseau</surname><given-names>KP</given-names></name></person-group>, <etal>et al.</etal><article-title>Elevated serum levels of soluble interleukin-2 receptors in active pulmonary sarcoidosis: relative specificity and association with hypercalcemia</article-title>. <source>Sarcoidosis</source><year>1987</year>; <volume>4</volume>: <fpage>87</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">2821601</pub-id></mixed-citation></ref><ref id="bibr55-1479973119878713"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logan</surname><given-names>T</given-names></name><name><surname>Bensadoun</surname><given-names>E</given-names></name></person-group><article-title>Increased disease activity in a patient with sarcoidosis after high dose interleukin 2 treatment for metastatic renal cancer</article-title>. <source>Thorax</source><year>2005</year>; <volume>60</volume>: <fpage>610</fpage>–<lpage>611</lpage>.<pub-id pub-id-type="pmid">15994271</pub-id></mixed-citation></ref><ref id="bibr56-1479973119878713"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokomura</surname><given-names>K</given-names></name><name><surname>Suda</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Increased expression of the 25-hydroxyvitamin D(3)-1alpha-hydroxylase gene in alveolar macrophages of patients with lung cancer</article-title>. <source>J Clin Endocrinol Metab</source><year>2003</year>; <volume>88</volume>: <fpage>5704</fpage>–<lpage>5709</lpage>.<pub-id pub-id-type="pmid">14671156</pub-id></mixed-citation></ref><ref id="bibr57-1479973119878713"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoffels</surname><given-names>K</given-names></name><name><surname>Overbergh</surname><given-names>L</given-names></name><name><surname>Giulietti</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes</article-title>. <source>J Bone Miner Res</source><year>2006</year>; <volume>21</volume>: <fpage>37</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">16355272</pub-id></mixed-citation></ref><ref id="bibr58-1479973119878713"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unsal</surname><given-names>A</given-names></name><name><surname>Basturk</surname><given-names>T</given-names></name><name><surname>Koc</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>Renal sarcoidosis with normal serum vitamin D and refractory hypercalcemia</article-title>. <source>Int Urol Nephrol</source><year>2013</year>; <volume>45</volume>: <fpage>1779</fpage>–<lpage>1783</lpage>.<pub-id pub-id-type="pmid">22826146</pub-id></mixed-citation></ref><ref id="bibr59-1479973119878713"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berlin</surname><given-names>JL</given-names></name><name><surname>Palamaner Subash Shantha</surname><given-names>G</given-names></name><name><surname>Yeager</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>Serum vitamin D levels may not reflect tissue-level vitamin D in sarcoidosis</article-title>. <source>BMJ Case Rep</source><year>2014</year><comment>Epub ahead of print 24 March 2014</comment><comment>DOI: 10.1136/bcr-2014-203759</comment>.</mixed-citation></ref><ref id="bibr60-1479973119878713"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrayyef</surname><given-names>MZ</given-names></name><name><surname>DePapp</surname><given-names>Z</given-names></name><name><surname>Cave</surname><given-names>WT</given-names></name></person-group>, <etal>et al.</etal><article-title>Hypercalcemia in two patients with sarcoidosis and <italic>Mycobacterium avium</italic> intracellulare not mediated by elevated vitamin D metabolites</article-title>. <source>Am J Med Sci</source><year>2011</year>; <volume>342</volume>: <fpage>336</fpage>–<lpage>340</lpage>.<pub-id pub-id-type="pmid">21760475</pub-id></mixed-citation></ref><ref id="bibr61-1479973119878713"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falk</surname><given-names>S</given-names></name><name><surname>Kratzsch</surname><given-names>J</given-names></name><name><surname>Paschke</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Hypercalcemia as a result of sarcoidosis with normal serum concentrations of vitamin D</article-title>. <source>Med Sci Monit Int Med J Exp Clin Res</source><year>2007</year>; <volume>13</volume>: <fpage>CS133</fpage>–<lpage>CS136</lpage>.</mixed-citation></ref><ref id="bibr62-1479973119878713"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basile</surname><given-names>JN</given-names></name><name><surname>Liel</surname><given-names>Y</given-names></name><name><surname>Shary</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Increased calcium intake does not suppress circulating 1,25-dihydroxyvitamin D in normocalcemic patients with sarcoidosis</article-title>. <source>J Clin Invest</source><year>1993</year>; <volume>91</volume>: <fpage>1396</fpage>–<lpage>1398</lpage>.<pub-id pub-id-type="pmid">8386185</pub-id></mixed-citation></ref><ref id="bibr63-1479973119878713"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>PH</given-names></name><name><surname>De Olazabal</surname><given-names>J</given-names></name><name><surname>Bell</surname><given-names>NH</given-names></name></person-group><article-title>Evidence for abnormal regulation of circulating 1 alpha,25-dihydroxyvitamin D in patients with sarcoidosis and normal calcium metabolism</article-title>. <source>J Clin Invest</source><year>1980</year>; <volume>66</volume>: <fpage>852</fpage>–<lpage>855</lpage>.<pub-id pub-id-type="pmid">7419722</pub-id></mixed-citation></ref><ref id="bibr64-1479973119878713"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamada</surname><given-names>K</given-names></name><name><surname>Nagai</surname><given-names>S</given-names></name><name><surname>Tsutsumi</surname><given-names>T</given-names></name></person-group>, <etal>et al.</etal><article-title>Ionized calcium and 1,25-dihydroxyvitamin D concentration in serum of patients with sarcoidosis</article-title>. <source>Eur Respir J</source><year>1998</year>; <volume>11</volume>: <fpage>1015</fpage>–<lpage>1020</lpage>.<pub-id pub-id-type="pmid">9648949</pub-id></mixed-citation></ref><ref id="bibr65-1479973119878713"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>JS</given-names></name><name><surname>Gacad</surname><given-names>MA</given-names></name><name><surname>Anders</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Biochemical indicators of disordered vitamin D and calcium homeostasis in sarcoidosis</article-title>. <source>Sarcoidosis</source><year>1986</year>; <volume>3</volume>: <fpage>1</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">3033783</pub-id></mixed-citation></ref><ref id="bibr66-1479973119878713"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alberts</surname><given-names>C</given-names></name><name><surname>van den Berg</surname><given-names>H.</given-names></name></person-group><article-title>Calcium metabolism in sarcoidosis. A follow-up study with respect to parathyroid hormone and vitamin D metabolites</article-title>. <source>Eur J Respir Dis</source><year>1986</year>; <volume>68</volume>: <fpage>186</fpage>–<lpage>194</lpage>.<pub-id pub-id-type="pmid">3699120</pub-id></mixed-citation></ref><ref id="bibr67-1479973119878713"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krikorian</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Wasman</surname><given-names>J</given-names></name></person-group><article-title>Parathyroid hormone-related protein: an unusual mechanism for hypercalcemia in sarcoidosis</article-title>. <source>Endocr Pract</source><year>2011</year>; <volume>17</volume>: <fpage>e84</fpage>–<lpage>86</lpage>.<pub-id pub-id-type="pmid">21550945</pub-id></mixed-citation></ref><ref id="bibr68-1479973119878713"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Raalte</surname><given-names>DH</given-names></name><name><surname>Goorden</surname><given-names>SM</given-names></name><name><surname>Kemper</surname><given-names>EA</given-names></name></person-group>, <etal>et al.</etal><article-title>Sarcoidosis-related hypercalcaemia due to production of parathyroid hormone-related peptide</article-title>. <source>BMJ Case Rep</source>; <year>2015</year><comment>Epub ahead of print 9 July 2015</comment><comment>DOI: 10.1136/bcr-2015-210189</comment>.</mixed-citation></ref><ref id="bibr69-1479973119878713"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeimer</surname><given-names>HJ</given-names></name><name><surname>Greenaway</surname><given-names>TM</given-names></name><name><surname>Slavin</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Parathyroid-hormone-related protein in sarcoidosis</article-title>. <source>Am J Pathol</source><year>1998</year>; <volume>152</volume>: <fpage>17</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">9422518</pub-id></mixed-citation></ref><ref id="bibr70-1479973119878713"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fierer</surname><given-names>J</given-names></name><name><surname>Burton</surname><given-names>DW</given-names></name><name><surname>Haghighi</surname><given-names>P</given-names></name></person-group>, <etal>et al.</etal><article-title>Hypercalcemia in disseminated coccidioidomycosis: expression of parathyroid hormone-related peptide is characteristic of granulomatous inflammation</article-title>. <source>Clin Infect Dis</source><year>2012</year>; <volume>55</volume>: <fpage>e61</fpage>–<lpage>e66</lpage>.<pub-id pub-id-type="pmid">22670039</pub-id></mixed-citation></ref><ref id="bibr71-1479973119878713"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandian</surname><given-names>MR</given-names></name><name><surname>Morgan</surname><given-names>CH</given-names></name><name><surname>Carlton</surname><given-names>E</given-names></name></person-group>, <etal>et al.</etal><article-title>Modified immunoradiometric assay of parathyroid hormone-related protein: clinical application in the differential diagnosis of hypercalcemia</article-title>. <source>Clin Chem</source><year>1992</year>; <volume>38</volume>: <fpage>282</fpage>–<lpage>288</lpage>.<pub-id pub-id-type="pmid">1371724</pub-id></mixed-citation></ref><ref id="bibr72-1479973119878713"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bucht</surname><given-names>E</given-names></name><name><surname>Eklund</surname><given-names>A</given-names></name><name><surname>Toss</surname><given-names>G</given-names></name></person-group>, <etal>et al.</etal><article-title>Parathyroid hormone-related peptide, measured by a midmolecule radioimmunoassay, in various hypercalcaemic and normocalcaemic conditions</article-title>. <source>Acta Endocrinol (Copenh)</source><year>1992</year>; <volume>127</volume>: <fpage>294</fpage>–<lpage>300</lpage>.<pub-id pub-id-type="pmid">1449040</pub-id></mixed-citation></ref><ref id="bibr73-1479973119878713"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heijckmann</surname><given-names>AC</given-names></name><name><surname>Huijberts</surname><given-names>MSP</given-names></name><name><surname>De Vries</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Bone turnover and hip bone mineral density in patients with sarcoidosis</article-title>. <source>Sarcoidosis Vasc</source><year>2007</year>; <volume>24</volume>: <fpage>51</fpage>–<lpage>58</lpage>.</mixed-citation></ref><ref id="bibr74-1479973119878713"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heijckmann</surname><given-names>AC</given-names></name><name><surname>Drent</surname><given-names>M</given-names></name><name><surname>Dumitrescu</surname><given-names>B</given-names></name></person-group>, <etal>et al.</etal><article-title>Progressive vertebral deformities despite unchanged bone mineral density in patients with sarcoidosis: a 4-year follow-up study</article-title>. <source>Osteoporos Int</source><year>2008</year>; <volume>19</volume>: <fpage>839</fpage>–<lpage>847</lpage>.<pub-id pub-id-type="pmid">18256778</pub-id></mixed-citation></ref><ref id="bibr75-1479973119878713"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolland</surname><given-names>MJ</given-names></name><name><surname>Wilsher</surname><given-names>ML</given-names></name><name><surname>Grey</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Bone density is normal and does not change over 2 years in sarcoidosis</article-title>. <source>Osteoporos Int</source><year>2015</year>; <volume>26</volume>: <fpage>611</fpage>–<lpage>616</lpage>.<pub-id pub-id-type="pmid">25172384</pub-id></mixed-citation></ref><ref id="bibr76-1479973119878713"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bours</surname><given-names>S</given-names></name><name><surname>de Vries</surname><given-names>F</given-names></name><name><surname>van den Bergh</surname><given-names>JPW</given-names></name></person-group>, <etal>et al.</etal><article-title>Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort</article-title>. <source>Osteoporos Int</source><year>2016</year>; <volume>27</volume>: <fpage>1603</fpage>–<lpage>1610</lpage>.<pub-id pub-id-type="pmid">26630976</pub-id></mixed-citation></ref><ref id="bibr77-1479973119878713"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oshagbemi</surname><given-names>OA</given-names></name><name><surname>Driessen</surname><given-names>JHM</given-names></name><name><surname>Pieffers</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis</article-title>. <source>Osteoporos Int</source><year>2017</year>; <volume>28</volume>: <fpage>2859</fpage>–<lpage>2866</lpage>.<pub-id pub-id-type="pmid">28638981</pub-id></mixed-citation></ref><ref id="bibr78-1479973119878713"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saidenberg-Kermanac’h</surname><given-names>N</given-names></name><name><surname>Semerano</surname><given-names>L</given-names></name><name><surname>Nunes</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: a cross sectional study on 142 patients</article-title>. <source>Arthritis Res Ther</source><year>2014</year>; <volume>16</volume>: <fpage>R78</fpage>.<pub-id pub-id-type="pmid">24655357</pub-id></mixed-citation></ref><ref id="bibr79-1479973119878713"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolland</surname><given-names>MJ</given-names></name><name><surname>Wilsher</surname><given-names>ML</given-names></name><name><surname>Grey</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Randomised controlled trial of vitamin D supplementation in sarcoidosis</article-title>. <source>BMJ Open</source><year>2013</year>; <volume>3</volume>: <fpage>e003562</fpage>.</mixed-citation></ref><ref id="bibr80-1479973119878713"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amin</surname><given-names>S</given-names></name><name><surname>LaValley</surname><given-names>MP</given-names></name><name><surname>Simms</surname><given-names>RW</given-names></name></person-group>, <etal>et al.</etal><article-title>The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach</article-title>. <source>Arthritis Rheum</source><year>1999</year>; <volume>42</volume>: <fpage>1740</fpage>–<lpage>1751</lpage>.<pub-id pub-id-type="pmid">10446876</pub-id></mixed-citation></ref><ref id="bibr81-1479973119878713"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>CS</given-names></name><name><surname>Yeung</surname><given-names>JH</given-names></name><name><surname>Vandermeer</surname><given-names>B</given-names></name></person-group>, <etal>et al.</etal><article-title>Bisphosphonates for steroid-induced osteoporosis</article-title>. <source>Cochrane Database Syst Rev</source><year>2016</year>; <volume>10</volume>: <fpage>CD001347</fpage>.<pub-id pub-id-type="pmid">27706804</pub-id></mixed-citation></ref><ref id="bibr82-1479973119878713"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amiche</surname><given-names>MA</given-names></name><name><surname>Albaum</surname><given-names>JM</given-names></name><name><surname>Tadrous</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis</article-title>. <source>Osteoporos Int J</source><year>2016</year>; <volume>27</volume>: <fpage>1989</fpage>–<lpage>1998</lpage>.</mixed-citation></ref><ref id="bibr83-1479973119878713"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boon</surname><given-names>ES</given-names></name><name><surname>Cozijn</surname><given-names>D</given-names></name><name><surname>Brombacher</surname><given-names>PJ</given-names></name></person-group><article-title>Enhanced production of calcitriol, and hypercalcaemia in a patient with sarcoidosis provoked by daily intake of calciol</article-title>. <source>Eur J Clin Chem Clin Biochem</source><year>1993</year>; <volume>31</volume>: <fpage>679</fpage>–<lpage>681</lpage>.<pub-id pub-id-type="pmid">8292670</pub-id></mixed-citation></ref><ref id="bibr84-1479973119878713"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarathi</surname><given-names>V</given-names></name><name><surname>Karethimmaiah</surname><given-names>H</given-names></name><name><surname>Goel</surname><given-names>A</given-names></name></person-group><article-title>High-dose vitamin D supplementation precipitating hypercalcemic crisis in granulomatous disorders</article-title>. <source>Indian J Endocrinol Metab</source><year>2017</year>; <volume>21</volume>: <fpage>815</fpage>–<lpage>819</lpage>.<pub-id pub-id-type="pmid">29285441</pub-id></mixed-citation></ref><ref id="bibr85-1479973119878713"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sodhi</surname><given-names>A</given-names></name><name><surname>Aldrich</surname><given-names>T.</given-names></name></person-group><article-title>Vitamin D supplementation: not so simple in sarcoidosis</article-title>. <source>Am J Med Sci</source><year>2016</year>; <volume>352</volume>: <fpage>252</fpage>–<lpage>257</lpage>.<pub-id pub-id-type="pmid">27650228</pub-id></mixed-citation></ref><ref id="bibr86-1479973119878713"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capolongo</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>LHR</given-names></name><name><surname>Accardo</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Vitamin-D status and mineral metabolism in two ethnic populations with sarcoidosis</article-title>. <source>J Investig Med</source><year>2016</year>; <volume>64</volume>: <fpage>1025</fpage>–<lpage>1034</lpage>.</mixed-citation></ref><ref id="bibr87-1479973119878713"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiani</surname><given-names>A</given-names></name><name><surname>Abedini</surname><given-names>A</given-names></name><name><surname>Adcock</surname><given-names>IM</given-names></name></person-group>, <etal>et al.</etal><article-title>Association between vitamin D deficiencies in sarcoidosis with disease activity, course of disease and stages of lung involvements</article-title>. <source>J Med Biochem</source><year>2018</year>; <volume>37</volume>: <fpage>103</fpage>–<lpage>109</lpage>.<pub-id pub-id-type="pmid">30581345</pub-id></mixed-citation></ref><ref id="bibr88-1479973119878713"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bansal</surname><given-names>AS</given-names></name><name><surname>Bruce</surname><given-names>J</given-names></name><name><surname>Hogan</surname><given-names>PG</given-names></name></person-group>, <etal>et al.</etal><article-title>An assessment of peripheral immunity in patients with sarcoidosis using measurements of serum vitamin D3, cytokines and soluble CD23</article-title>. <source>Clin Exp Immunol</source><year>1997</year>; <volume>110</volume>: <fpage>92</fpage>–<lpage>97</lpage>.<pub-id pub-id-type="pmid">9353154</pub-id></mixed-citation></ref><ref id="bibr89-1479973119878713"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kavathia</surname><given-names>D</given-names></name><name><surname>Buckley</surname><given-names>JD</given-names></name><name><surname>Rao</surname><given-names>D</given-names></name></person-group>, <etal>et al.</etal><article-title>Elevated 1,25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis</article-title>. <source>Respir Med</source><year>2010</year>; <volume>104</volume>: <fpage>564</fpage>–<lpage>570</lpage>.<pub-id pub-id-type="pmid">20071158</pub-id></mixed-citation></ref><ref id="bibr90-1479973119878713"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Infante</surname><given-names>JR</given-names></name><name><surname>Pacheco</surname><given-names>C</given-names></name><name><surname>Torres-Avisbal</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Pulmonary activity in sarcoidosis: 67 Ga uptake quantification and plasma determination of 1,25-dihydroxyvitamin D</article-title>. <source>Rev Esp Med Nucl</source><year>2002</year>; <volume>21</volume>: <fpage>275</fpage>–<lpage>280</lpage>.<pub-id pub-id-type="pmid">12206740</pub-id></mixed-citation></ref><ref id="bibr91-1479973119878713"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>OP</given-names></name></person-group><article-title>Hypercalcemia in granulomatous disorders: a clinical review</article-title>. <source>Curr Opin Pulm Med</source><year>2000</year>; <volume>6</volume>: <fpage>442</fpage>–<lpage>447</lpage>.<pub-id pub-id-type="pmid">10958237</pub-id></mixed-citation></ref><ref id="bibr92-1479973119878713"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>RR</given-names></name><name><surname>Rybicki</surname><given-names>BA</given-names></name><name><surname>Rao</surname><given-names>DS</given-names></name></person-group><article-title>Calcium and vitamin D in sarcoidosis: how to assess and manage</article-title>. <source>Semin Respir Crit Care Med</source><year>2010</year>; <volume>31</volume>: <fpage>474</fpage>–<lpage>484</lpage>.<pub-id pub-id-type="pmid">20665397</pub-id></mixed-citation></ref><ref id="bibr93-1479973119878713"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>JS</given-names></name><name><surname>Sharma</surname><given-names>OP</given-names></name><name><surname>Diz</surname><given-names>MM</given-names></name></person-group>, <etal>et al.</etal><article-title>Ketoconazole decreases the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia</article-title>. <source>J Clin Endocrinol Metab</source><year>1990</year>; <volume>70</volume>: <fpage>1090</fpage>–<lpage>1095</lpage>.<pub-id pub-id-type="pmid">2318934</pub-id></mixed-citation></ref><ref id="bibr94-1479973119878713"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bia</surname><given-names>MJ</given-names></name><name><surname>Insogna</surname><given-names>K</given-names></name></person-group><article-title>Treatment of sarcoidosis-associated hypercalcemia with ketoconazole</article-title>. <source>Am J Kidney</source><year>1991</year>; <volume>18</volume>: <fpage>702</fpage>–<lpage>705</lpage>.</mixed-citation></ref><ref id="bibr95-1479973119878713"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barré</surname><given-names>PE</given-names></name><name><surname>Gascon-Barré</surname><given-names>M</given-names></name><name><surname>Meakins</surname><given-names>JL</given-names></name></person-group>, <etal>et al.</etal><article-title>Hydroxychloroquine treatment of hypercalcemia in a patient with sarcoidosis undergoing hemodialysis</article-title>. <source>Am J Med</source><year>1987</year>; <volume>82</volume>: <fpage>1259</fpage>–<lpage>1262</lpage>.<pub-id pub-id-type="pmid">3605143</pub-id></mixed-citation></ref><ref id="bibr96-1479973119878713"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Leary</surname><given-names>TJ</given-names></name><name><surname>Jones</surname><given-names>G</given-names></name><name><surname>Yip</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis</article-title>. <source>N Engl J Med</source><year>1986</year>; <volume>315</volume>: <fpage>727</fpage>–<lpage>730</lpage>.<pub-id pub-id-type="pmid">3755800</pub-id></mixed-citation></ref><ref id="bibr97-1479973119878713"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thumfart</surname><given-names>J</given-names></name><name><surname>Müller</surname><given-names>D</given-names></name><name><surname>Rudolph</surname><given-names>B</given-names></name></person-group>, <etal>et al.</etal><article-title>Isolated sarcoid granulomatous interstitial nephritis responding to infliximab therapy</article-title>. <source>Am J Kidney</source><year>2005</year>; <volume>45</volume>: <fpage>411</fpage>–<lpage>414</lpage>.</mixed-citation></ref><ref id="bibr98-1479973119878713"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huffstutter</surname><given-names>JG</given-names></name><name><surname>Huffstutter</surname><given-names>JE</given-names></name></person-group><article-title>Hypercalcemia from sarcoidosis successfully treated with infliximab</article-title>. <source>Sarcoidosis Vasc</source><year>2012</year>; <volume>29</volume>: <fpage>51</fpage>–<lpage>52</lpage>.</mixed-citation></ref><ref id="bibr99-1479973119878713"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dwarakanathan</surname><given-names>A</given-names></name><name><surname>Ryan</surname><given-names>WG</given-names></name></person-group><article-title>Hypercalcemia of sarcoidosis treated with cellulose sodium phosphate</article-title>. <source>Bone Miner</source><year>1987</year>; <volume>2</volume>: <fpage>333</fpage>–<lpage>336</lpage>.<pub-id pub-id-type="pmid">2851338</pub-id></mixed-citation></ref><ref id="bibr100-1479973119878713"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waron</surname><given-names>M</given-names></name><name><surname>Weissgarten</surname><given-names>J</given-names></name><name><surname>Gil</surname><given-names>I</given-names></name></person-group>, <etal>et al.</etal><article-title>Sarcoid nephrocalcinotic renal failure reversed by sodium cellulose phosphate</article-title>. <source>Am J Nephrol</source><year>1986</year>; <volume>6</volume>: <fpage>220</fpage>–<lpage>223</lpage>.<pub-id pub-id-type="pmid">3740131</pub-id></mixed-citation></ref><ref id="bibr101-1479973119878713"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Littlewood</surname><given-names>T</given-names></name><name><surname>Hunter</surname><given-names>A</given-names></name><name><surname>Beck</surname><given-names>P</given-names></name></person-group>, <etal>et al.</etal><article-title>Treatment of hypercalcaemia in sarcoidosis with flurbiprofen</article-title>. <source>Br Med J Clin Res Ed</source><year>1983</year>; <volume>287</volume>: <fpage>1762</fpage>–<lpage>1763</lpage>.</mixed-citation></ref><ref id="bibr102-1479973119878713"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyrier</surname><given-names>A</given-names></name><name><surname>Valeyre</surname><given-names>D</given-names></name><name><surname>Bouillon</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Different mechanisms of hypercalciuria in sarcoidosis. Correlations with disease extension and activity</article-title>. <source>Ann N Y Acad Sci</source><year>1986</year>; <volume>465</volume>: <fpage>575</fpage>–<lpage>586</lpage>.<pub-id pub-id-type="pmid">3014962</pub-id></mixed-citation></ref><ref id="bibr103-1479973119878713"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuss</surname><given-names>M</given-names></name><name><surname>Pepersack</surname><given-names>T</given-names></name><name><surname>Gillet</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Calcium and vitamin D metabolism in granulomatous diseases</article-title>. <source>Clin Rheumatol</source><year>1992</year>; <volume>11</volume>: <fpage>28</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">1582115</pub-id></mixed-citation></ref><ref id="bibr104-1479973119878713"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzato</surname><given-names>G</given-names></name><name><surname>Colombo</surname><given-names>P</given-names></name></person-group><article-title>Nephrolithiasis as a presenting feature of chronic sarcoidosis: a prospective study</article-title>. <source>Sarcoidosis Vasc</source><year>1996</year>; <volume>13</volume>: <fpage>167</fpage>–<lpage>172</lpage>.</mixed-citation></ref><ref id="bibr105-1479973119878713"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemann</surname><given-names>J</given-names></name></person-group><article-title>Composition of the diet and calcium kidney stones</article-title>. <source>N Engl J Med</source><year>1993</year>; <volume>328</volume>: <fpage>880</fpage>–<lpage>882</lpage>.<pub-id pub-id-type="pmid">8441433</pub-id></mixed-citation></ref><ref id="bibr106-1479973119878713"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>WC</given-names></name></person-group><article-title>Urinary calculi in hypercalcemic states</article-title>. <source>Endocrinol Metab Clin North Am</source><year>1990</year>; <volume>19</volume>: <fpage>839</fpage>–<lpage>849</lpage>.<pub-id pub-id-type="pmid">2081514</pub-id></mixed-citation></ref><ref id="bibr107-1479973119878713"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohmer</surname><given-names>J</given-names></name><name><surname>Hadjadj</surname><given-names>J</given-names></name><name><surname>Bouzerara</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Serum 1,25(OH)<sub>2</sub> vitamin D and 25(OH) vitamin D ratio for the diagnosis of sarcoidosis-related uveitis</article-title>. <source>Ocul Immunol Inflamm</source><year>2018</year>; <volume>5</volume>: <fpage>1</fpage>–<lpage>7</lpage>.</mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000937 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000937 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |